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 A common pattern in systems designed to transport liquids and gases, such as the 
vascular and respiratory systems, is the use of branched tubular structures to create a 
network that interconnects the entire body.  The cellular cues required for generating 
these complex networks are not well understood.  To identify components involved in 
generating branched tubular networks we are studying the Drosophila melanogaster 
tracheal (respiratory) system.  The Drosophila larval tracheal system is composed of 
approximately 10,000 interconnected tubes which serve to transport oxygen and other 
gases throughout the body. The branching and tubulogenesis (the formation of an open 
space or lumen that extends throughout the length of a branch to make it a tube) seen 
during Drosophila tracheal system development may parallel similar processes seen in 
other organisms.  The molecular and genetic tools available for Drosophila provide us an 
excellent opportunity to identify factors required in branching and lumen formation.  
A forward genetic screen of the X chromosome was conducted to isolate lethal 
mutations affecting branching and lumen formation in tracheal terminal cells of 
Drosophila.  Tracheal terminal cells are specialized cells that undergo subcellular 
branching and tubulogenesis, and are responsible for transporting gases and exchanging 
gases in hypoxic tissues.  Thirty-two lines with mutations affecting different aspects of 
branching and lumen formation were identified.  Of these 32 we focused on five 
   iv 
lines in which tracheal terminal cells undergo essentially normal branching, but are 
unable to generate a functional lumen.  These mutants have been mapped to discrete 
genetic intervals using a recombination mapping strategy.  The mapping has been further 
refined for two of these five lines by using a combination of single nucleotide 
polymorphisms (SNP) and P-element recombination frequencies allowing us to identify a 
small number of candidate genes for each of these mutations.  Additionally, for one of 
these mutants we have identified the causative gene as Zpr1 (Zinc-finger protein 1), an 
evolutionarily conserved protein characterized by two C4 zinc fingers and two conserved 
homology domains.  
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  A common architecture in systems designed for the transport of liquids and gases, 
such as the vascular and respiratory systems, is the use of branched, tubular structures to 
create a network that interconnects the entire organism.  To establish these complex 
networks, groups of cells must undergo a variety of morphological and cellular changes 
that result in the assembly of the functional fully-interconnected tubular network.  
Despite the widespread use this common structural design, the cellular and molecular 
mechanisms required for establishing these transport networks are not well understood.  
To gain insight into the genes required to achieve the morphological and cell 
rearrangements used for generating interconnected tubular networks we are studying the 
development of the larval tracheal (respiratory) system of the fly Drosophila 
melanogaster.  The larval tracheal system in Drosophila is a network of thousands of 
interconnected tubes that serve to transport oxygen and other gases throughout the body. 
 
Development of the Drosophila embryonic tracheal system 
The construction of the Drosophila tracheal system begins early in 
embryogenesis, when 10 bilateral segmentally repeated groups of ∼80 cells within the 
embryonic ectoderm are fated to become tracheal tissue through the expression of the 
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bHLH-PAS domain transcription factor trachealess (Samakovlis et al., 1996A and Wilk 
et al., 1996).  Expression of trachealess is followed by the invagination of these tracheal 
placodes to form tracheal sacs.  Soon after formation, each sac undergoes a series of 
coordinated and stereotyped branching and tubulogenesis events, starting at mid-
embryogenesis.  These early outgrowth events are mediated through the secretion of the 
FGF ligand, Branchless (Bnl) by cells surrounding the tracheal sacs (Sutherland et al., 
1996).  Tracheal cells respond to these signaling cells through the ligand-dependent 
activation of the tracheal specific FGF receptor Breathless (Btl) (Lee et al., 1996).  
Activation of the Btl receptor in tracheal cells results in the coordinated and stereotypical 
branching pattern that forms the embryonic tracheal system.  Within the embryonic 
tracheal system, specialized cells at the ends of branches called terminal cells are 
specified through the expression of the transcription factor blistered, the Drosophila 
homolog of the mammalian serum response factor (Guillemin et al., 1996). 
  
Development of the Drosophila larval tracheal system 
During larval development a second wave of Bnl signaling from hypoxic cells 
induces additional branching and outgrowth in terminal (Jarecki et al., 1999).  Once the 
initial branching required for tracheal cells to reach their target tissue is completed, the 
tracheal terminal cells must undergo a subsequent lumenogenesis step to create the 
hollow space, or lumen, through which the gas must travel (Reviewed in Ghabrial et al., 
2003).  This lumen formation step is cellularly distinct from the tubes that form during 
the development of the embryonic tracheal system.  The embryonic tracheal system is 
comprised of two basic tube types.  The first type (primary branches) of tube in the 
  3 
tracheal system are multicellular structures that are comprised of a single layer of 
epithelial cells wrapped into a tubular shape (Figure 1.1).  Because primary branches 
arise through migration and intercalation of small clusters of cells that can organize 
themselves into tubes, cross section of these branches reveals many intercellular junctions 
that provide an airtight seal for the lumen (Samakovlis, et al., 1996A).  Secondary 
branches are unicellular tubes that are made from extended individual cells that wrap 
around the long axis of the cell to create a single autocellular junction, or seam, which 
runs the entire length of the cell (Samakovlis, et al., 1996B).  
The last tube type in the tracheal system is comprised by terminal cells.  Terminal 
cells, where gas exchange between the tracheal system and hypoxic tissues takes place 
(Figure 1.2), are characterized by having a completely subcellular lumen with no cellular 
junctions.  Also, in contrast to the entirely stereotyped branching and lumen formation 
observed during early tracheal morphogenesis, terminal cell branch outgrowth is a 
dynamic process that is mainly controlled by the extent of hypoxia a target tissue is 
experiencing (Jarecki, 1999 and Ghabrial and Krasnow, 2006).  This final growth ensures 
that terminal cells that provide oxygen to hypoxic tissue will have sufficient branches that 
can be utilized for efficient gas exchange.   
 
Lumen formation 
The establishment of a functional lumen is an important step in achieving the 
interconnectivity required for efficient transport of liquids or gases in branched tubular 
networks.  Despite the wide variety of branched tubular networks seen in nature, it is 
thought that the organization of most tubular structures involves a layer of polarized cells 
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in which the apical surface of the cells faces the lumen.  Groups of cells can undergo a 
variety of morphological and cell rearrangements to generate a tube with a functional 
polarized apical lumen.  The primary branches in the Drosophila tracheal system are 
created through a process called wrapping (Lubarsky and Krasnow, 2003).  In this 
process a polarized epithelial sheet curls until its edges meet, forming a seal.  In this case, 
the apical surfaces of all cells encompassing this sheet now face the hollow end or lumen 
of this tube, and the basal surface is exposed to the inside of the animal (Shim, et al., 
2001).  The secondary branches in the Drosophila tracheal system employ a type of tube 
formation process called budding.  As in wrapping, this type of tube also arises from a 
polarized epithelial sheet.  In this case, movement of cells in an outward direction from 
the sheet creates the tubular structure.  The creation of tubes through a wrapping or 
budding process depends on a previously established polarized epithelial sheet of cells.  
Tubes can also arise from unpolarized cells cells in a processes called cavitation, cord 
hollowing and cell hollowing (Lubarsky and Krasnow, 2003).  The final products of these 
processes are structurally similar to the tubes created by wrapping or budding, in that 
they all result in the creation of a polarized tubular structure.  In cavitation and cord 
hollowing, a hollow structure arises from inside a mass of unpolarized cells through 
either the specific elimination of cells (cavitation) or cell movement and rearrangements 
(cord hollowing) (Lubarsky and Krasnow, 2003).  All of the previously described tube 
formation processes require the use of groups of cells to establish a lumen.   
In contrast to these multicellular tubes, Drosophila terminal cells are able to 
create a completely subcellular lumen.  To create a such a lumen, terminal cells employ a 
process called cell hollowing.  In cell hollowing, a single cell establishes a lumen in the 
  5 
absence of cell-cell junctions or positional cues from neighboring cells.  The specific 
instructional components involved in the creation, maintenance and remodeling of a 
completely subcellular lumen are not well characterized.   
The observation that most tubular structures display polarized apical lumen has 
led to the idea that although tubular structures can be created through distinct 
morphological and cell rearrangements, all seem to depend on a similar set of cellular 
cues.  The first of these cellular cues involves the establishment of apical and basal 
polarity.  This early polarization step ensures that all cellular components involved in 
lumenogenesis target the future lumen to the same location.  Although this had been 
proposed as an important step in the creation of a subcellular lumen, the specific role of 
molecules known to effect the establishment of apical/basal polarity in various cell types 
has not been described in tracheal terminal cells.  Recent work has shown that 
components of PAR-polarity complex are required for proper terminal cell branching and 
lumen formation (Jones and Metzstein, 2011).  This suggests that terminal cells must 
establish an apical/basal identity in order for development to occur.  Recent evidence also 
suggests that once polarized, cells may utilize changes in the localization of different 
cytoskeletal components, such as microtubules, to establish a scaffold upon which the 
lumen can be built (Schottenfeld-Roames and Ghabrial, 2012).  The idea that a molecular 
scaffold must be created to establish a site for the generation of a nascent lumen has been 
argued from experiments showing that during the initial steps in lumen formation in cell 
culture experiments and the vascular development in zebrafish, vacuolar structures can be 
seen diffused throughout the cell, but later in the lumenogenesis process, these structures 
seem to fuse and coalesce to form the lumen (Kamei et al., 2006).  Additional work has 
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shown that various components known to be involved in general vesicle trafficking also 
play a role in generating a functional lumen in an in vitro model of lumenogenesis 
(Bayless and Davis, 2002).  More recent work has show that the GTPase Rab35 is a key 
regulator of lumen formation in terminal cells and that changes in its subcellular 
localization have striking effects on lumen growth (Schottenfeld-Roames and Ghabrial, 
2012).  Despite our expanding knowledge of general lumen formation, many of the 
components required to specifically generate a subcellular lumen remain uncharacterized.   
 
Summary 
In this thesis, I present my studies on mapping and identifying lethal mutations on 
the Drosophila X chromosome that have an affect on lumen formation in tracheal 
terminal cells.  In Chapter 2, I describe the mapping strategies and data we obtained by 
mapping five genes that are required for lumen formation and one gene that is required 
for proper branch/lumen coordination obtained from a previously conducted screen.  In 
Chapter 3, I describe my molecular studies on one of these lumenless genes Zpr1 (Zinc-
finger protein 1) and the role that it plays in mediating RTK (receptor tyrosine kinase) 
signaling in the tracheal system.  In Chapter 4, I analyze proteins that have been 
previously shown to interact with Zpr1 by cell culture experiments, and test their specific 
roles in the development of the tracheal system of Drosophila.  Lastly, in Chapter 5, I 
describe the use of the Drosophila larval tracheal system as a model for the study of the 
cerebral cavernous malformations, a human genetic disease characterized by defects in 
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Figure 1.1. Cross-section of the three types of tubes that comprise the Drosophila 
larval tracheal system.  Multicellular tubes contain multiple cell-cell junctions.  
Unicellular tubes are made from single cells and contain a single autocellular junction.  
Terminal cells generate branches that contain a completely subcellular lumen, and do not 
























The other primary branches, except those that form the
dorsal trunk, also give rise to secondary branches. Twelve
secondary branches typically arise from the Tr5 visceral
branch. As in the dorsal branch, when the proximal cells of
the visceral branch begin to intercalate and elongate, the more
distal cells remain clustered (Fig. 4A). Subsequently, the
clustered cells begin to separate and each forms a discrete
branch on the gut (Fig. 4B). Although most secondary
branches form at the ends of primary branches, several arise
at internal positions (Fig. 4D, arrows). 
Terminal branches are subcellular tubes formed
within long cytoplasmic processes
Most secondary branch cells sprout many terminal branches
beginning late in embryogenesis and continuing throughout the
larval period. A single cell like the ones shown in Fig. 4A and
B forms an extensive array of branches that densely cover its
target (Fig. 4C). The subset of secondary branch cells that send
out terminal branches we call terminal cells. 
Terminal branches arise as cytoplasmic extensions of
terminal cells. A close up view of formation of the first
C. Samakovlis and others 
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Fig. 1. General structure and
pattern of tracheal branching in
embryogenesis. (A) Cutaway
view of a major tracheal tube and
branch point. (B) Cross-sections
of a multicellular primary branch
with two intercellular junctions, a
unicellular secondary branch with
an autocellular junction and a
subcellular terminal branch with
no junctions. (C-H) Development
of the left side of the tracheal
system from stage 11 to 16
visualized by staining the lumen
with antisera TL-1 (C-F) and
mAb2A12 (G, H). Anterior is left
and dorsal is up in all figures.
Square bracket, fifth tracheal
hemisegment (Tr5).
(I) Development of Tr5. The six
primary branches (dorsal branch,
DB; dorsal trunk anterior, DTa;
dorsal trunk posterior, DTp;
visceral branch, VB; lateral trunk
anterior, LTa; lateral trunk
posterior/ganglionic branch,
LTp/GB) are highlighted at stage
12. Secondary branches are
highlighted at stage 15. At stage
16, single terminal branches
(highlighted) begin to sprout
from the end of each secondary
branch (except the three fusion
branches which are indicated by
arrowheads at stage 15). In the
late embryo and larva, many
more terminal branches form at
these positions. The points of
transition from secondary to
terminal branches are
approximate. Solid lines, lumen
of Tr5; dashed lines, adjacent
tracheal hemisegments; arrow,
Tr5-Tr6 dorsal trunk fusion
point; TC, transverse connective;





Figure 1.2.  Drosophila larval tracheal terminal cells.  Branching patterns of terminal 
cells can be assayed by cytoplasmic GFP-labeling (A).  Subcellular gas-filling in terminal 









































Bayless, K.J. and G.E. Davis (2002). The Cdc42 and Rac1 GTPases are required for 
capillary lumen formation in three-dimensional extracellular matrices. J Cell Sci 115, 
1123-36. 
  
Ghabrial, A., et al. (2003). Branching morphogenesis of the Drosophila tracheal system. 
Annu Rev Cell Dev Biol 19, 623-47. 
  
Ghabrial, A. and M.A. Krasnow (2006). Social interactions among epithelial cells during 
tracheal branching morphogenesis.  Nature 441,746-749. 
  
Chung S, et al. (2009). Serrano (sano) functions with the planar cell polarity genes to 
control tracheal tube length. PLoS Genet. 5, e1000746  
  
Guillemin, K., et al. (1996). The pruned gene encodes the Drosophila serum response 
factor and regulates cytoplasmic outgrowth during terminal branching of the tracheal 
system. Development 122, 1353-62. 
  
Jarecki, J., E. Johnson, M.A. Krasnow (1999).  Oxygen regulation of airway branching in 
Drosophila is mediated by branchless FGF. Cell 99, 211-20. 
  
Jones, T. and M. Metzstein (2011). A novel function for the PAR complex in subcellular 
morphogenesis of tracheal terminal cells in Drosophila melanogaster. Genetics 189, 153-
64. 
  
Kamei, M., et al. (2006). Endothelial tubes assemble from intracellular vacuoles in vivo. 
Nature 442, 453-6. 
  
Lee, T.,  et al. (1996). Regulated Breathless receptor tyrosine kinase activity required to 
pattern cell migration and branching in the Drosophila tracheal system. Genes and 
Development 10, 2912-2921 
  
Levi, B.P., A.S. Ghabrial and M.A. Krasnow (2006). Drosophila talin and integrin genes 
are required for maintenance of tracheal terminal branches and luminal organization. 
Development 133, 2383-93. 
  
Lubarsky, B. and M.A. Krasnow (2003). Tube morphogenesis: making and shaping 
biological tubes. Cell 112, 19-28. 
  
Samakovlis, C., et al. (1996). Development of the Drosophila tracheal system occurs by a 




Samakovlis, C., et al. (1996). Genetic control of epithelial tube fusion during Drosophila 
tracheal development. Development 122, 3531-6. 
  
Schottenfeld-Roames J, Ghabrial AS. (2012). Whacked and Rab35 polarize dynein-
motor-complex-dependent seamless tube growth. Nat Cell Biol.  March 11.  
  
Shim, K., K. Blake, J. Jack, and M.A. Krasnow. (2001) The Drosophila ribbon gene 
encodes a nuclear BTB domain protein that promotes epithelial migration and 
morphogenesis. Development 128, 4923-4933. 
  
Sutherland, D., et al. (1996). branchless encodes a Drosophila FGF homolog that controls 
tracheal cell migration and the pattern of branching. Cell 87, 1091-101. 
 . 
Wilk R., Weizman I. and Shilo BZ. (1996). trachealess encodes a bHLH-PAS protein that 










































MAPPING AND IDENTIFICATION OF MUTATIONS AFFECTING  
 
GAS-FILLING IN DROSOPHILA TRACHEAL 
 





  The Drosophila larval tracheal system provides an excellent opportunity to 
identify novel genes involved in the establishment of branched tubular networks.  
Branched tubular networks such as the vascular and respiratory systems are a common 
organ architecture that function to transport liquids and gases.  To identify components 
involved in generating these types of branched tubular networks, a forward genetic screen 
of the Drosophila X chromosome aimed at identifying lethal mutations that have defects 
in tracheal terminal cell development was performed previously (Metzstein and Krasnow, 
unpublished).  Terminal cells are specialized cells that undergo subcellular branching and 
tubulogenesis, and are responsible for transporting gases and exchanging gases in 
hypoxic tissues (Guillemin et al., 1996; Jarecki et al., 1999).  The screen identified 32 
lines with mutations affecting different aspects of branching and lumen formation.  Of 
these 32, we focus here on five lines in which tracheal terminal cells undergo essentially 
normal branching, but are unable to generate a functional lumen, and one line which 
displays a branch/lumen coordination defect.  We have mapped five of these mutants to 
 
  12 
discrete genetic intervals using a visible marker recombination mapping strategy.  The 
mapping has been further refined for two of these five lines by using a combination of 
single nucleotide polymorphisms (SNP) and transposable element (TE) markers and has 
allowed us to identify a small number of candidate genes for each of these mutations. 
  
Materials and methods 
Identification of lethal mutations on the Drosophila X chromosome  
affecting lumen formation in tracheal terminal cells 
EMS-generated lethal mutations on the Drosophila X chromosome were 
identified by the inability of homozygous mutants to live to the wandering L3 stage 
(Metzstein and Krasnow, unpublished results).  Individual lethal mutations were then 
assayed for terminal cell defects by using clonal analysis.  For all clonal analysis, we 
used the mosaic analysis with a repressible cell marker (MARCM) system to generate 
positively marked, homozygous mutant cells within heterozygous animals (Lee and Luo, 
1999).  Briefly, mutant X chromosomes containing the Flippase recombination target site 
(FRT) FRT19A were placed in trans to a wild-type chromosome containing the same FRT 
(Xu and Rubin, 1993).  The clone generating stock also contains the tracheal-specific 
driver btl-GAL4 a UAS-GFP reporter as well as the repressor of GAL4-mediated 
transcription btl-Gal80 (Shiga et al., 1996).  We then induced recombination by heat 
shocking 0-6 hour old embryos containing the heat-shock inducible flippase hsFLP122 at 
38° for 45 minutes.  This heat shock induces the expression of the flippase which 
mediates recombination between FRT sites and generates homozygous mutant cells that 
are positively marked by GFP.  For all clonal experiments control chromosomes are 
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FRT19A.  MARCM analysis was done on the following X-linked lethal alleles, 13A, 31ZZ, 
33UU, 5A, 17CC and 25C.  The tracheal specific promoter breathless (btl) was used to 
positively mark homozygous mutant cells in the following stock: y w btl-Gal80, FRT19A, 
hsFLP122; btl-Gal4, UAS-GFP (Metzstein and Krasnow, unpublished results). 
 
Mapping lethal mutations on X chromosome 
The lethality associated with mutations on the X chromosome was mapped by 
first crossing each lethal X chromosome to an X chromosome carrying multiple visible 
markers (sc cv ct v g2 f FRT19A).  Trans-heterozygous F1 females were mated to males of 
genotype Df(1)64c18, g1 sd1/Dp(1;2;Y)w+.  Viable hemizygous male progeny from this 
cross were scored for the visible markers (Figure 2.1).   Males used in the F1 cross 
contained a genomic duplication of the white gene allowing us to identify recombinants 
occurring between the v and g genes (which are eye color markers).  This strategy 
allowed us to map each mutation to a discrete genetic interval on the X chromosome.  
 
Identifying single nucleotide polymorphisms (SNPs) in  
recombinant animals 
Our initial mapping strategy allowed us to place individual lethal mutations 
within specific genetic intervals.  To further refine the location of each mutation we used 
our recombination strategy to identify viable male flies that had undergone a single 
recombination event within the genetic interval previously identified as containing the 
lethal allele.  The position of the single recombination event from the original viable 
marker was determined by using single nucleotide polymorphisms (SNPs) which differed 
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between the lethal containing chromosome and the multiply-marked chromosome.  To 
identify these SNPs we first designed ∼1000bp PCR amplicons (using Primer 3) within 
intergenic regions spanning the interval between the visible markers that contained the 
lethal of interest.  After the amplicon PCR conditions were optimized for each primer 
pair, the amplicons from both marked and mutant chromosomes were sequenced and the 
sequences compared for differences including SNPs and InDels.  We then examined if 
the polymorphisms altered restriction digest enzyme sites in the amplicons, and if so we 
used restriction digest of amplicons for genotyping.  For SNPs identified in which 
restriction digest enzyme sites were not altered, we used sequencing to type the markers.  
For mutant lines 33UU and 31ZZ (both of which mapped between ct and v) we identified 
22 informative marker amplicons, and used each to map the relative position of each 
lethal mutation (Table 2.1). 
  
Mapping lethality with respect to transposable element insertions 
To further refine the position of the lethal mutation associated with mutant lines 
within the ct and v genetic interval, we employed a meiotic recombination mapping 
strategy similar to the previous mapping experiments, but in this case we mapped the 
position of the lethal mutation with respect to transposable element (TE) insertions.  Fly 
stocks harboring single visibly marked transposable element insertions are available from 
various Drosophila stock centers.  The exact genomic position for each of these 
transposable elements has been characterized (Table 2.2).  Combining the position and 
the visible marker (typically a w+ eye color or y+ body color marker) allows for efficient 
identification of recombinant events close to the lethal allele.  For lethal mutants that 
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were mapped to the ct and v genetic interval, we obtained TE lines whose location had 
also been mapped to the same interval, and used these lines to refine our mapping data 
(Table 2.2).  We first produced trans-heterozygote females by crossing each lethal mutant 
line to individual TE lines.  We then crossed approximately 400 of these trans-het F1 
females to males, and scored for the absence of marker (w+ or y+) associated with each 
TE line in individual viable hemizygous male progeny.  Finally, by scoring flanking 
genetic markers, this allowed us to map the genomic position of lethal mutation as being 
to the left or right of each individual TE insertion.   
 
Candidate gene RNAi analysis 
The tracheal specific breathless promoter was used to drive UAS-RNAi 
transgenes directed against individual candidate genes in the tracheal system.  Lethality 
was assayed by using Act5C-GAL4 to ubiquitously drive the expression of each RNAi 
transgene (Ito et al., 1997).  Candidate genes were identified by searching FlyBase for 
genes located within the previously identified genomic regions whose gene ontology 
terms and lists of biological processes include cellular pathways thought to be involved in 










Mutations required for branching and lumen formation in  
Drosophila terminal tracheal cells 
A forward genetic mosaic screen of lethal mutations on the X chromosome was 
conducted by using the MARCM system to generate positively (GFP) marked 
homozygous mutant cells in heterozygous animals.  Homozygous mutant cells were then 
scored for tracheal branching or air-filling defects by using a combination of fluorescence 
microscopy and brightfield optics to visualize terminal branching patterns and air-filling, 
respectively.  Of the 900 lines that were scored, a class of mutations, that we refer to as 
lumenless was identified by their inability to generate gas-filled lumens.  From this 
lumenless class of mutants, we focused on five individual mutant lines.  In addition, we 
examined one mutant line in which lumen formation occurred, showed a defect in 
branch/lumen coordination.  To map and clone these six mutants, we first mapped the 
lethality associated with each mutation to a discrete genetic interval (Figure 2.2).  For two 
of these mutants, we refined this interval further by using a combination of SNP mapping 
and mapping relative to available TE insertions. 
 
Mutant line 5A 
Homozygous 5A mutant cells display seemingly wild-type branching patterns, but 
are unable to generate a gas-filled lumen (Figure 2.3).  For preliminary mapping of this 
mutant line, 85 individual recombinants were scored from trans-heterozygous females 
carrying the 5A lethal chromosome.  Viable recombinants placed the 5A lethal mutation 
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in the genetic interval between the cv and ct genes, representing a ∼1.9 Mb region of 
DNA.  Previously, a lethal mutation affecting gas-filling in tracheal terminal cells was 
identified in a mutant line designated oog (out of gas) which also mapped to the same cv 
and ct interval as 5A, and subsequently identified as a mutation in rabconnectin-3α 
(Metzstein, et al., unpublished results).  To test for the possibility that 5A may represent a 
new allele of oog we performed a complementation test.  Since the oog mutation had 
been mapped and cloned, transgenic flies carrying a transgene containing the oog 
genomic locus on the 2nd chromosome were available.  We crossed males of genotype 
oog/Y; P{oog+}/+ to 5A/FM7c virgins and scored nonbalancer containing F1 females.  Of 
the 87 oog/5A females scored, 39 were w+ genotype (indicating the presence of the oog+ 
transgene) and 48 were w- (indicating the absence of the oog+ transgene).  These results 
indicate that 5A and oog are not allelic and represent mutations in distinct genes.   
Analysis of the 5A interval led us to identify candidate genes within the genetic 
interval (Table 2.3).  We then tested the function of four candidate genes by RNAi 
knock-down.  Of the four genes tested (Marf, Pat1, CG3973 and CGC), only Marf 
(mitochondrial assembly regulatory factor) was lethal when driven by the Actin 
promoter, and produced a variable lumenless phenotype when driven by the tracheal 
specific driver breathless.  The Marf protein is predicted to have GTPase activity and 
could play a role in terminal cell lumenogenesis as a regulator of vesicle trafficking and 





Mutant line 33UU 
Homozygous 33UU mutant cells show branching defects and are unable to 
generate a functional lumen (Figure 2.4).  For the initial mapping analysis, 88 individual 
recombinants were scored from trans-heterozygous females carrying the lethal 33UU 
chromosome and the marker chromosome.  Viable recombinants placed the 33UU lethal 
mutation in the genetic interval between the ct and v genes, representing a ∼3.2Mb 
interval.  We refined this mapping by SNP analysis in recombinants in which a single 
recombination event had occurred within the ct-v interval (see Materials and Methods).  
A total of 99 single recombinant flies were collected from each recombination class (46 
v+ ct and 53 v ct+) and subsequently tested for single nucleotide polymorphisms that 
would allow us to distinguish between the mutagenized chromosome and the 
chromosome used for our mapping studies.  This analysis placed our mutation between 
SNPs XD4 and XD10 (Table 2.1), a region of ∼189kb.  To further refine the position of 
the lethal mutation associated with 33UU, we mapped the position of the lethal mutation 
with respect to transposable element insertions (see Materials and Methods).  Using a 
combination of SNPs and TE lines, described in Table 2.2, we were able to further 
narrow the interval containing the lethal mutation in 33UU to a ∼100kb region.  During 
the time this data was obtained, the current version of the Drosophila genome assembly 
predicted multiple genes within this 100kb region. We obtained lines containing UAS-
RNAi constructs for all these predicted genes and used these to assay gene function in the 
tracheal system (Table 2.3).  However, tracheal terminal cells expressing any of these 
constructs exhibit a wild-type phenotype.  Recently, this region within the Drosophila 
genome has been re-annotated to now include portions of a single 140kb gene named 
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megalin.  The megalin gene encodes a low-density lipoprotein receptor and experimental 
evidence suggests that it may be involved in chitin-based cuticle development and 
endocytosis (Riedel, et al. 2011); functions which have been shown to be essential in 
tracheal development (Devine et al., 2005, Tonning et al., 2005).  Our mapping data 
suggest that the causative mutation in mutant line 33UU lies somewhere within the 
megalin gene and provides an excellent starting point for its discovery.  
 
Mutant line 13A 
Terminal cells homozygous mutant for 13A display an inability to generate 
functional air-filled lumens.  Fifty-nine individual recombinants were scored from trans-
heterozygous females carrying the lethal 13A chromosome and the marker chromosome.  
Viable recombinants placed the 13A lethal mutation in the genetic interval between the sc 
and cv genes, representing a ∼3Mb region.  We examined the interval for possible 
candidate genes and used a RNAi strategy to test their function in tracheal terminal cells 
(Table 2.2).  Of the five genes (rala, cut up, vap33-1, lava lamp and fd3f) assayed by 
RNAi using dsRNA expressed from the ubiquitous Actin promoter, all except cut up 
showed a lethal phenotype.  When RNAi was performed in a tissue-specific manner using 
the breathless promoter, the gene rala (ras- related protein) was the only gene in which 
tracheal cells showed defects in gas-filling.  The Rala protein is predicted to have GTPase 
activity and PDZ-binding properties and these functions may be involved in processes 
that may also play a role in terminal cell development (Jones and Metzstein, 2011, 
Schottenfeld-Roames and Ghabrial, 2012).  This result now provides a reasonable 
candidate gene for sequence analysis in the 13A mutant line.  
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Mutant line 17CC 
Eighty-six individual recombinants were scored from trans-heterozygous females 
carrying the lethal 17CC chromosome and the marker chromosome.  We were unable to 
place the lethal mutation in a specific genetic interval because no lethality was observed 
in the F2 generation.  The source of this surprising result is that the w+ genomic 
duplication used to score eye color markers in recombinant animals, also rescues the 
lethality of 17CC.  This allows us to place the lethal mutation associated with 17CC in 
the duplicated chromosomal region.  This duplication encompasses the cytological bands 
2D2-3D3. We then examined the duplicated segment for possible candidate genes, and 
used a RNAi strategy to test their function in tracheal terminal cells (Table 2.2).  
Disruption of all six genes (vinculin, egghead, syntaxin4, klp3A, CG3071 and CG14054) 
resulted in viable animals when function was assayed by RNAi using dsRNA expressed 
from the ubiquitous Actin promoter.  Interestingly, when RNAi was performed in a 
tissue-specific manner using the breathless promoter, the gene CG14054 showed a 
variable gas-filling defect.  This result is intriguing, in that it suggests that CG14054 may 
be solely required in the tracheal system.  Follow up experiments should be aimed at 
confirming the degree of RNAi knockdown that is being achieved as well as a 
quantification of this variable defect to confirm this result.  Nevertheless, CG14054 
provides an interesting gene to investigate by sequence analysis in the 17CC mutant line.  
 
Mutant line 31ZZ 
One hundred ten individual recombinants were scored from trans-heterozygous 
females carrying the lethal 31ZZ chromosome and the marked chromosome.  Viable 
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recombinants placed the 31ZZ lethal mutation in the genetic interval between the ct and v 
genes, a ∼3.2Mb region. We refined this mapping by performing SNP analysis in 
recombinants in which a single recombination event had occurred within the ct-v interval 
(See Materials and Methods).  A total of 38 single recombinant flies were collected from 
each recombination class (8 ct v+ and 30 ct+ v) and subsequently tested for SNPs that 
would allow us to distinguish between the mutagenized chromosome and the reference 
chromosome used for our mapping studies.  We followed this by mapping with respect to 
transposable element insertion sites.  By combining our SNP mapping data with our TE 
mapping results we were able to narrow the 31ZZ genetic interval from a ∼115kb region 
(between the SNPs XD11 and XA37, Table 2.1) to a ∼72kb region (between TE insertion 
PBac{WH}-f02398 and SNP XA37).  The genes included in this interval were then 
assayed for mutations by sequencing.  A single mutation was identified in the gene Zinc-
finger protein 1 (Zpr1).  Additional sequencing and cloning data of mutant line 31ZZ will 
be discussed in the following chapter.  
Initial SNP mapping placed the 31ZZ mutation in the same genetic interval with a 
previously identified lethal mutation, 25C, allowing for the possibility that these 
mutations may represent different alleles of the same gene.  25C (also called crazy 
lumens) was originally identified by a lumenal over-growth and excessive gas-filling 
phenotype in tracheal terminal cells (Metzstein and Krasnow, unpublished).  By 
additional SNP and transposable element mapping we have ruled out the possibility that 




Mutant line 25C 
Previous mapping data on the crazy lumens mutant line had placed the causative 
mutation in a region between the TE insertions KG00121 and KG0172.  This ∼65kb 
region encompassed 14 genes and was small enough to try to identify the causative 
mutation in this mutant line by sequencing.  We subsequently attempted to sequence all 
of the genes within this region but were unable to find mutations in any of the genes for 
which we were able to obtain quality sequence data (Table 2.4). We were unable to 
obtain quality sequence data for three remaining genes, probably due to the duplicated 
nature of these genes.  Instead, we tested for function using an RNAi approach targeted at 
two of the three genes.  Of both assayed genes, one line displayed a strong lumenless 
phenotype when the RNAi construct was expressed in the tracheal system (Table 2.6).  
This phenotype is distinct from the lumenal overgrowth defect seen in the mutant line.  
Since our RNAi knock-down is likely to represent the loss-of-function phenotype the 
mutant line may represent a gain-of-function phenotype.  These results place CG32708 as 
likely to harbor the causative mutation, and present the possibility that 25C may be a 
neomorphic allele of this gene.  Additional sequencing and rescue experiments must be 
performed to identify the mutation in the crazy lumens mutant line, but the possibility 
that the distinct mutant and RNAi knockdown phenotypes may represent important allelic 
differences and may provide powerful genetic tools for the dissection of the molecular 






 Mutants isolated from a forward genetic screen of the Drosophila X chromosome 
were mapped to discrete genetic intervals using a visible marker recombination mapping 
strategy.  For some of these mutants the mapping has been further refined using a 
combination of single nucleotide polymorphisms and transposable element mapping.  
These mapping experiments have led to the molecular cloning of one mutant line 31ZZ, 
which will be discussed in the following chapter.  Additionally specfic candidate genes 
were identified for the remaining lumenless class of mutant lines .  In particular, the 
mapping data and recent re-annotation of the Drosophila genome provide a single 
candidate gene for mutant line 33UU.  Sequence analysis should identify the lesion in the 
mutant line and may place the previously uncharacterized megalin gene in the 
lumenogenesis pathway.  Recent evidence suggests that Megalin is involved in chitin-
based cuticle development and regulation of endocytosis, processes which have both been 
shown to be important for the creation of a lumen and the regulation of lumen size 
(Riedel, et al., 2011).  These two processes may occur at different times during 
lumenogenesis.  Ultrastructural analysis of this mutant line will provide clues as to 
whether Megalin is playing a role early in the lumenogenesis process through specific 
endocytic activity, or relatively late in the lumen development through its role in 
regulating chitin development.  
Additionally, the sequencing and candidate gene analysis performed for mutant 
line 25C also provides a single candidate gene and may also provide an allelic series that 
can be used to elucidate the molecular function of CG32708.  Together, these three 
mutant lines now offer uncharacterized novel genes, or annotated genes whose function 
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has not been previously implicated in the development of tracheal terminal cells.  
Interestingly, many of these uncharacterized genes may have mechanistic functions that 






















Table 2.1. Primer sequences and positions of identified SNPs used for mapping 
genes within the ct and v interval.  
   ID Forward primer Reverse primer Position  
Restriction 
Enzyme 
XA35 AATGAGGGTGGAACAACAGC ACGCCAAGTCCTTGCATTAC 8,602,357 HpyCH4IV 
XA36 TCAGAAGCCACACGTTGAAG GCGTTTGCCTTCCAGTTAAG 8,855,190 RsaI 
XB22 GCTGCCATTAGTGGCTCTTC AACTGGAGCAATGGAACCTG 8,953,086 NlaIV 
XD11 TGCCTTCTTATTTGGACCAC GCAGCTATTTTACAGCGACAAC 8,986,868 AluI 
XD12 TTTGGCTCTTGGATGGAAAC AACACGTATCCTGGGAGTGG 9,034,427 NspI 
XB23 AGCTTGTGGGATGCATTTTC TCTCACAAACCGAACAGCAG 9,056,658 SfaNI 
XD13 CCGAAAGCTGCATAAAAAGC CTTACATCCGCACGAAAGTG 9,069,631 Seq. 
XA37 CTGGCAGCGAATTAAAAAGC TTCCCAACGCCTACTACACC 9,102,640 DraI 
XD1 TGGAGGTGAAACCCTCACTC ACCGCGTTCAACTTTAATGG 9,186,760 HpyCH4III 
XD2 GCCAATGTTGTTGCAGTGTC GCAAACGCAAGGCTAGAATC 9,248,679 HpyCH4IV 
XD9 ACGCTTAAATGAAGGGAAGC CAATTTTTGTAGCCCACTGTTC 9,252,816 Seq. 
XD10 CCATCCACCGACATATTGC CGGAGTTCACTTGTGTGGAG 9,258,870 RsaI 
XD5 TGGGTTCTCTGGTTCTTTCG CGACAGAGTGATGTGGGATG 9,272,560 Seq. 
XD6 CCCTTGCCCCCTTTACTAAC TCATCTTTTGCGTTGCTTTG 9,313,455 MluI 
XB25 CCTGTCATGTTTTCCGTGTG TTACGCTGTGCCTCAAACAG 9,336,673 MfeI 
XD7B CTTCTTTCTGCGGCTCATTC AAGCGAAAAATGGCAATGTC 9,371,304 Seq. 
XD3A AGATGGCAGGGTGAATAACG AACATCTGCGTTGCCTTTTC 9,414,689 Seq. 
XD8 AGAGCCTTGATTGTGGATGG TGTGGCAGAGAGTCCTTGTG 9,436,596 Seq. 
XD4 TCGATCCGTAGGTCAATTACTC CTGGTTTGTCCATGTTAGATCG 9,447,815 XmnI 
XB26 GGAGAAGCACGAGACTTTGG CCTGCGCCTTATCACTAAGC 9,488,764 NcoI 
XB32 TTGTCTGGCTGACTGGACTG ATCTGGAACCAAAGCCAATG 10,389,240 HpyCH4III 
XB33 TGTTCGCGCATAAATCAGAG GTTGTTGGTGCTTTGTGGTG 10,537,641 BstXI  
Based on Drosophila reference genome release 5.44. Restriction enzyme list indicates 








Table 2.2. Transposable element insertions used for mapping genes within the ct and 
v interval.   
Mutant Transgene Insertion FlyBase ID Position Recombinants Direction 
25C P{SuPor-P}-KG00121 FBst0013043 8,961,856 N.D. N.A. 
 P{SuPor-P}-KG01702 FBst0013473 9,026,634 N.D. N.A. 
31ZZ P{XP}-d06942 FBst1011231 6,875,836 1/8,400 Right 
 PBac{WH}-f02398 FBst1017711 9,030,683 3/9,000 Right 
 PBac{WH}--f06347 FBst1020516 9,081,578 9/51,200 Left 
33UU PBac{RB}-e03903 FBst1015338 9,228,462 6/N.D. Right 
 PBac{WH}-f05850 FBst1020151 9,230,574 5/N.D. Right 
 PBac{WH}-f04515 FBst1019207 9,359,639 4/N.D. Left 
 PBac{XP}-d01684 FBst1009351 9,391,423 4/N.D. Left 
 P{SuPor-P}-KG03908 FBst0013969 9,404,760 5/N.D. Left 
 
Based on Drosophila reference genome release 5.44.  Direction indicates position of 















Table 2.3. List of candidate genes assayed by RNAi for lethality and tracheal 
defects. 
 
Mutant Candidate Gene VDRC Number Lethality* 
Tracheal 
Defects † 
5A Marf V40478 Yes Variable 
 Pat1 V27308 No WT 
 CG3973 V34772 No WT 
 C3G V21306 No WT 
13A Lava lamp V40382 Yes WT 
 Vap-33-1 V30404 Yes WT 
 Fd3f V37745 Yes WT 
 Cut up V43115 No WT 
 Rala V43622 Yes Lumenless 
17CC Vinculin V34585 No WT 
 CG3071 V29588 No WT 
 CG14054 V32088 No Variable 
 Egghead V10137 No WT 
 Klp3A V35974 No WT 
 Syntaxin4 V32413 No WT 
33UU Bcl7-like V20410 Yes WT 
 CG15316 V32560 No WT 
 CG12650 V22783 No WT 
 CG12654 V1109 Yes WT 
25C Bx42 8264R-1 No WT 
 CG7039 V26007 No WT 
 CG7766 V52572 No WT 
 CG6999 V41828 No WT 
 CG7033 V41190 No WT 
 CG32708 V49325 No Lumenless 
 CG7246 V34256 No WT 
 
*Lethality tested with Act5C-GAL4  
†Tracheal defects tested with btl-GAL4 
WT= wild-type 
Variable= low penetrance lumenless 
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Table 2.4. List of 25C candidate genes sequenced and assayed by RNAi for tracheal 
defects.   
 
Candidate Gene Sequenced Mutation 
RNAi 
Phenotype 
CG10970 Yes No N.D. 
CG7267 Yes No N.D. 
CG15366 Yes No N.D. 
CG7246 Yes No N.D. 
HP1b Yes No N.D. 
APC4 Yes No WT 
CG32708 No N/A Lumenless 
CG32706 No N/A N.D. 
CG6999 No N/A WT 
CG7033 Yes No WT 
CG7766 Yes No WT 
Bx42 Yes No WT 
CG7039 Yes No WT 
AP-1gamma Yes No N.D. 
 






















Figure 2.1:  Genetic map of the Drosophila X chromosome and recombination 
mapping scheme.  Drosophila X chromosome harboring multiple visible markers was 
used to create trans-heterozygote females containing a marked chromosome and a lethal 
chromosome (in bold).  Trans-heterozygote females were then crossed to males 
containing a duplication of the w+ gene, and viable progeny were scored for presence or 
absence of visible markers.  The genes sc and y are not allelic, but are so close they 
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Figure 2.2:  Genetic map of the Drosophila X chromosome.  Mutants recovered from 
forward genetic screen of the X chromosome were mapped to discrete genetic intervals 
using a multipoint recombination mapping strategy.  Genetic loci for five mutants 































Figure 2.3.  5A homozygous mutant terminal cells display a normal branching, but 
fail to make gas-filled lumen.  Wild-type branching is assayed by cytoplasmic GFP (A) 
and brightfield optics are used to visualize gas-filling defect (A’).  Bar, 200µm, dashed 
























Figure 2.4.  33UU homozygous mutant terminal cells display a variable branching 
defects and are unable to generate functional gas-filled lumens. Branching is assayed 
by GFP (A) and brightfield optics are used to visualize gas-filling defect (A’).  Bar, 























Figure 2.5:  Identified SNPs within ct and v genetic interval.  Single Nucleotide 




















































































Figure 2.6.  25C homozygous mutant terminal cells display a branch/lumen 
coordination defect.  25C mutant cells display branching defects (A) and convoluted 
lumens (arrow) in some branches (A’).  Bar, 200µm, dashed lines indicate proximal end 
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DROSOPHILA ZPR1 (ZINC FINGER PROTEIN 1) IS REQUIRED  
 
DOWNSTREAM OF BOTH EGFR AND FGFR SIGNALING  
 





  Branched tubular networks, such as the vascular and respiratory systems, are a 
common structural design used to facilitate the transport of liquids and gases throughout 
the body.  The cellular cues and signaling required for generating these complex 
networks, and tailoring each structure for a specific need (e.g., transporting liquid vs. 
transporting gases) are not well understood.  To identify components involved in tubular 
network formation we are studying the Drosophila melanogaster tracheal (respiratory) 
system.  The larval tracheal system in Drosophila is composed of a network of 
approximately 10,000 interconnected tubes which serve to transport oxygen and other 
gases throughout the body (Ghabrial et al., 2003).  To construct this elaborate tubular 
network, cells within the tracheal epithelium first undergo a series of coordinated and 
stereotyped branching and tubulogenesis events during mid-embryogenesis.  These 
events are primarily regulated by a Fibroblast Growth Factor ligand (FGF) and receptor 
(FGFR), encoded by the branchless (bnl) and breathless (btl) genes respectively 
(Sutherland et al., 1996, Lee et al., 1996).  These Bnl and Btl mediated early outgrowth 
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events provide a cellular framework for what will eventually be the larval tracheal 
system, through which gases can enter the body and diffuse to target tissues.  The mature 
larval tracheal system can be subdivided into three morphologically distinct tube types 
(Lubarsky and Krasnow, 2003).  The first type are multicellular structures in which a 
polarized layer of epithelial cells is shaped to create a tube (Shim et al., 2001).  Cross 
section of these branches reveals intercellular junctions that maintain a permeability 
barrier for the lumen, the hollow space through which gases are transported (Samakovlis 
et al., 1996A).  The second type of tubes are unicellular and are made from single cells 
that wrap around their long axis and form an autocellular junction.  The third type of 
tracheal tubes form in a specific cell type named terminal cells (Guillemin et al. 1996).  
Terminal cells are characterized by their extensive subcellular branching and their 
completely subcellular lumens, that form without cell junctions.  In contrast to the 
stereotyped branching and lumen formation observed during early tracheal 
morphogenesis, terminal cell branch outgrowth is a dynamic process and is controlled by 
the extent of hypoxia in target tissues (Jarecki et al. 1996 and Ghabrial and Krasnow, 
2006).  Thus, terminal may provide a model for understanding the development of fine 
capillaries within the vertebrate vasculature whose development also depends on tissue 
oxygen status (Ghabrial et al., 2003).  To identify factors required for branching and 
lumen formation specifically in terminal cells, we have analyzed a mutant obtained in a 
forward genetic mosaic screen of the X chromosome (Metzstein and Krasnow, 
unpublished results).  We show here that this screen has identified a mutation in the gene 
Zpr1 (zinc-finger protein 1).  Zpr1 is an evolutionarily conserved protein characterized by 
two C4 zinc fingers and two Zpr1-specific conserved homology domains and was first 
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identified in mammalian cells as a cytoplasmic protein that was capable of binding the 
intracellular domain of the unactivated EGF receptor (Galcheva et al., 1996).  We find 
that Zinc Finger Protein 1 (Zpr1) is required for terminal cell lumen formation and also 
show that Zpr1 function lies downstream of both the FGF receptor (FGFR) and the 
epidermal growth factor receptor (EGFR).  
  
Materials and Methods 
Fly stocks and genetics 
All flies were reared on standard media and raised at 25ºC.  Control chromosomes 
used for clonal analysis were FRT19A or FRTG13.  MARCM (Lee and Luo, 1999) analysis 
was done on the following alleles, Zpr131ZZ, EGFRK05115 (Bloomington 10385), EGFRf2 
(Bloomington 2768), and EGFRtop-co(a gift from M. Fuller).  The btl-GAL4 driver was 
used for all tissue-specific experiments (Shiga et al., 1996).  Positively marked 
homozygous mutant cells were generated using the stocks: y w P{w+ btl-Gal80}, FRT19A, 
hsFLP122; btl-Gal4, UAS-GFP and y w hsFLP122; P{w+ tub-Gal80}, FRTG13; btl-Gal4, 
UAS-GFP (a gift from S. Luschnig).  The following EGFR RNAi and dominant negative 
transgenic lines were used in the gas-filling assays: y1 v1; P{TRiP.JF01368}attP2, 
(Bloomington 25781), y1 v1; P{TRiP.JF01084}attP2, (Bloomington 31526), y1 v1; 
P{TRiP.JF02384}attP2, (Bloomington 36773), and y1 w*; P{UAS-Egfr.DN.B}29-77-1; 
P{UAS-Egfr.DN.B}29-8-1, (Bloomington 5364).  For all receptor tyrosine kinase 
epistasis experiments a y w P{w+ tub-Gal80}, FRT19A, hsFLP122; btl-Gal4, UAS-DsRed 
was used to generate MARCM clones that were homozygous mutant for Zpr1.  The 
following over-expression transgenes were used for epistasis experiments:  w*; 
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P{w[+mC]=Egfr.2.UAS}7-10, (Bloomington 9535), w*; 
P{w[+mC]=Egfr.2.A887T.UAS}8-2 (Bloomington 9533) and UAS-λbtl (Lee et al., 1996).  
The presence or absence of these transgenes in the MARCM mutants was determined by 
scoring the presence of either of the following YFP-expressing balancer chromosomes:  
w*; ry506 Dr1/TM3, P{Dfd-GMR-nvYFP}3, Sb1 (Bloomington 23231) w*; snaSco/CyO, 
P{Dfd-GMR-nvYFP} (Blomington 23230).   
 
Identification of mutation in mutant line 31ZZ 
The lethality associated with mutant line 31ZZ was mapped to ~72kb region 
(between TE insertion PBac{WH}-f02398 and SNP XA37) using multiple meiotic 
recombination mapping strategies and has been described in more detail in Chapter 2.  
All genes lying within this genetic interval were examined for mutations by sequencing 
trans-heterozygous females carrying the 31ZZ chromosome over a wild-type 
chromosome.  A single non-synonymous mutation was identified in the gene Zinc-finger 
protein 1 (Zpr1).  
 
Transgenes and cloning 
A 3.2 kb rescue transgene spanning the entire Zpr1 genomic locus as well as 949 
bp (base pairs) upstream of the gene was amplified by PCR (Primers in Table 3.1) and 
cloned into the NotI and PmeI restriction enzyme sites in the P[acman] transformation 
vector (Venken et al., 2006) and injected into flies carrying the VK00026 attB docking 
site on the 3rd chromosome for site-specific integration (Venken et al., 2006).  We 
obtained a plasmid containing Drosophila Zpr1 cDNA (LD37736, Gold Collection) from 
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the Drosophila Genomics Resource Center and PCR amplified the coding sequence for 
subsequent cloning (primers in Table 3.1).  The coding sequence of Zpr1 was then cloned 
into the pUAST+attP (a gift from Carl Thummel) transformation vector using the NotI 
and EcoRV restriction sites and injected into flies carrying the VK00027 attB docking site 
on the 3rd chromosome.  All transgenic injections were done by Genetic Services Inc. 
 
Terminal cell branching and lumen quantification 
To determine the number of branches in both wild-type and mutant cells, we 
collected fluorescence images of GFP-labeled dorsal terminal cells.  Branches from 
these cells were traced manually using the NeuronJ plug-in for ImageJ (Meijering et al., 
2004).  Branch order was assigned by the following scheme: the single central branch 
encompassing the nucleus was designated as the primary branch of each cell; secondary 
branches arise directly from that primary branch; branches that arise from secondary 
branches were categorized as tertiary branches, which in turn give rise to quaternary 
branches.  To assay lumen formation in terminal cells, we used brightfield optics to 
visualize gas-filling.  Since mutants were either completely gas-filled or completely 
empty and we did not see partial gas-filling we used a binary scoring system in which 
individual cells were scored as either wild-type gas-filling or lumenless.  In experiments 
using tracheal specific RNAi or dominant negative transgenes we scored the lateral 






A mutant required for branching and lumen formation in  
Drosophila terminal tracheal cells 
To identify genes involved in tracheal terminal cell development, a forward 
genetic mosaic screen of lethal mutations on the X chromosome was performed by using 
the MARCM system to generate positively (GFP) labeled homozygous mutant cells in 
heterozygous animals (Lee and Luo, 1999).  Homozygous mutant cells were then scored 
for tracheal branching and air-filling defects by using a combination of fluorescence 
microscopy and brightfield optics to visualize terminal branching patterns and air-filling, 
respectively.  Among the 900 lines that were scored, a mutant designated 31ZZ was 
identified by its complete failure to generate air-filled lumens (Figure 3.1).  31ZZ mutant 
cells also show a significant but variable branching defect (Figure 3.1).    Wild-type 
terminal cells have a single central terminal branch from which secondary branches 
sprout, subsequent branching occurs from these secondary branches to generate tertiary 
branches and from these form quaternary branches. Wild-type cells also possess a single 
gas-filled lumen that runs through every branch class.  We find that 31ZZ mutants are 
able to generate a central branch and secondary branches, but fail to undergo tertiary and 
quaternary branching (Figure 3.1).  Additionally, we find that 31ZZ mutants fail to 
generate gas–filled lumen in all branch classes.  While the branching phenotype was 





31ZZ is an allele of Drosophila Zpr1 
To identify the causative mutation in 31ZZ we mapped the lethality to a discrete 
genetic interval on the X chromosome using a multipoint recombination mapping 
strategy.  This analysis allowed us to place the mutation in 31ZZ to the 3.3Mb 
(megabase) interval between the ct and v genes.  The interval containing 31ZZ was then 
refined by using available transposable element insertions as molecular markers of 
meiotic recombination events.  Lastly, to further refine our interval, single nucleotide 
polymorphisms (SNPs) were identified and scored in recombinants between ct and v 
allowing us to map the 31ZZ mutation to a 72kb interval containing nine genes.  
Sequencing of the genes in this region identified a single point mutation (an A to T 
transversion) in the first exon of the gene Zpr1.  The mutation results in a premature 
termination codon at amino acid position 58.  To confirm this mutation as the causative 
allele in 31ZZ, a 3.2 kb transgene spanning the Zpr1 genomic locus as well as 949 base 
pairs upstream of the gene was transformed into flies and subsequently tested for rescue 
of the lethality and gas-filling defect associated with 31ZZ.  We found a single copy of 
this transgene was able to rescue the lethality associated with 31ZZ, as well as the 
terminal cell lumenless defect (data not shown).  Additionally, we generated transgenic 
flies carrying a UAS-Zpr1-cDNA or UAS-Zpr1-cDNA-N-terminal tagged GFP transgene 
and found both were able to rescue the lumenless phenotype in 31ZZ mutant cells (data 





EGFR loss-of-function phenocopies the Zpr1 lumenless defect 
Zpr1 was first identified as a cytoplasmic protein that was capable of binding the 
intracellular domain of the unactivated EGF receptor (Galcheva et al., 1996).  Additional 
work later showed a role for EGFR signaling in the development of the embryonic 
tracheal system, therefore we hypothesized that Zpr1 was mediating an EGFR signaling 
cascade required for subcellular lumenogenesis (Jeon and Zinn, 2009).  This led us to test 
whether mutations in the EGFR would also have an effect on lumenogenesis.  We tested 
the effect of EGFR mutations on terminal cell development by examining terminal cells 
mutant for loss-of-function EGFR alleles.  Terminal cells mutant for any of these three 
null alleles of the EGFR (EGFRK05115, EGFRf2, and EGFRtop-co) resulted in some 
lumenless terminal cells.  In contrast to the robust lumenless phenotype of Zpr1 mutants, 
in which all mutant cells are lumenless, only a small percentage (around 15%) of terminal 
cells mutant for the EGFR display a lumenless phenotype (Figure 3.2D).  To determine 
whether this was a characteristic of the particular EGFR alleles used, or a broader 
phenomenon of EGFR signaling, we conducted a series of experiments using different 
manipulations to remove EGFR function (Figure 3.2).  We removed EGFR specifically in 
the tracheal system by using the tracheal specific btl-GAL4 driver to express multiple 
available EGFR-RNAi lines, as well as an EGFR Dominant negative transgene.  
Surprisingly, all methods used to remove EGFR function displayed at most a similar 
penetrance to the loss-of-function mosaic experiments.  These data suggest that other 
factors such as pathway redundancy through other RTKs or environmental factors such as 
hypoxic conditions may also function in regulating the lumen formation process. 
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We next tested if an increase in EGFR activity could induce lumen formation in 
tracheal terminal cells by over-expression of a wild-type version of the receptor as well as 
a constitutively active version.  We find that over-expression of either the wild-type or 
activated versions of the EGFR result in an increase in lumen formation, characterized by 
multiple air-filled lumens within a single cell, a finding consistent with previously 
published data (Jeon and Zinn, 2009) indicating a role for EGF signaling in tracheal cell 
development (Figure 3.3, A and B).  We decided to test whether Zpr1 lies downstream of 
the EGFR by testing the epistatic relationship of Zpr1 and the various EGFR over-
expression transgenes.  To test whether loss of Zpr1 could suppress either of the EGFR 
mediated overgrowth phenotypes, we made Zpr1 MARCM mosaics in which we 
employed the btl-GAL4 that positively marks mutant cells to simultaneously drive the 
expression of either of the UAS-EGFR transgenes.  We found that Zpr1 mutant cells that 
over-express either the wild type or activated form of the EGFR are lumenless (Figure 
3.3, D and E).  This finding is consistent with Zpr1 functioning downstream of the 
EGFR, which was first proposed from cell culture experiments (Galcheva et al., 1996)and 
now provides the first in vivo evidence for this pathway. 
 
Zpr1 lies downstream of multiple RTKs 
The weak penetrance of our EGFR loss of function experiments led us to consider 
the possibility that other active RTKs could be feeding into the Zpr1 pathway.  To test 
this, we tested the most well-studied active RTK in the Drosophila tracheal system, the 
FGFR Btl.  Tracheal cells mutant for FGFR loss of function alleles fail to outgrow or 
undergo branching, hindering our ability to test these alleles in the larval terminal cells 
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(Glazer and Shilo, 1991).  To bypass the early requirement of Btl, we tested the epistatic 
relationship of Zpr1 and FGFR by employing an activated form of the Btl receptor (λbtl).  
Overexpression of this activated form of the FGFR results in increased lumen formation 
which can be visualized by multiple air-filled lumens within single cells (Figure 3.3C).  
To test whether loss of Zpr1 could suppress this FGFR mediated overgrowth we made 
Zpr1 MARCM mosaics in which the btl-GAL4 which positively marks mutant cells also 
drives the expression of the UAS-btlλ transgene.  We find that all Zpr1 homozygous 
mutant cells display a Zpr1 lumenless phenotype indicating that Zpr1 is epistatic to the 
luminal overgrowth phenotype observed in FGFR overexpression (Figure 3.3F).  
Discussion 
 
To achieve complete interconnectivity, a branched tubular network such as the 
Drosophila larval tracheal system must first undergo extensive branching and fusion 
steps that begin during embryogenesis and continue throughout larval development 
(Samakovlis et al., 1996B).  Terminal cells must then undergo an additional intracellular 
lumen formation step to promote gas exchange.  We show here that Zpr1 is required for 
this lumenogenesis process, and is also involved in regulating branch outgrowth of 
terminal cells.  Zpr1 was initially identified as a protein that was able to bind the 
intracellular tail of the inactive EGFR, an interaction necessary for cell growth and 
division (Gangwani et al., 2005, Gangwani, 2006).  Although the EGFR has previously 
been shown to be involved early in tracheal cell migration, and is necessary for 
maintaining the structural of the tracheal system, specific downstream effectors have not 
been identified in the tracheal system (Cela and Llimargas, 2006, Nishimura et al., 2007).  
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To our knowledge, this is the first in vivo evidence that demonstrates that Zpr1 functions 
downstream of the EGFR, and that Zpr1 activity is required for a specific developmental 
process.  Additionally, our epistasis experiments show that Zpr1 lies downstream of 
multiple RTKs.  Initial experiments aimed at mapping the EGFR-Zpr1 binding domains 
showed that Zpr1 binds to the subdomains X and XI of the EGFR (Galcheva-Gargova et 
al., 1996). This region is composed of three α helices and is well conserved in other 
RTKs such as the platelet-derived growth factor (PDGF) and the FGFR (Hubbard, et al., 
1994).  The binding of Zpr1 to this conserved motif on different RTKs was confirmed for 
the PDGF but not the FGFR (Galcheva-Gargova et al., 1996).  Here we present the first 
genetic evidence that Zpr1 functions downstream of the FGFR in mediating lumen 
formation in terminal cells.  Although the amount of conservation at subdomains X and 
XI of the FGFR suggest that the downstream function of Zpr1 is mediated through their 
direct physical interaction, we have yet to test this hypothesis through co-
immunoprecipitation (Co-IP) experiments.  
 The finding that Zpr1 lies downstream of multiple RTKs allows us to propose a 
model that provides the cell with a method for interpreting various positional cues that 
help the cell determine whether it has reached hypoxic target tissue (Figure 3.4).  In our 
model, hypoxic tissue secreting FGF serves as a long-range signaling molecule that 
instructs the outgrowth and active migration of terminal cells towards hypoxic tissue.  
Hypoxic tissue additionally secretes EGF as a short-range signaling molecule that 
induces lumen formation.  Since lumen formation is an important step in mediating gas 
exchange between hypoxic tissue, the possible cross talk or redundancy between the 
FGFR and EGFR signaling cascades provide the cell with, a fail safe that can ensure 
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lumen formation occurs as well as an alternative method for modifying the amount of 























Table 3.1. List of primer sequences used for generating transgenic constructs.   
 










































Figure 3.1:  Zpr1 is required for branching and lumen formation in terminal cells.  
Mosaic L3 larvae were generated using the MARCM system.  Homozygous mutant cells 
are positively marked by the expression of GFP.  Tracheal cell branching and gas-filling 
patterns are characterized by using GFP (A, B) and brightfield microscopy (A’, B’), 
respectively. (A’’ and B’’) Tracing of the branching patterns of cells in A and B.  Wild-
type terminal cells undergo extensive branching and have a single air-filled lumen in each 
branch (A-A’’).  Zpr1 homozygous mutant cells exhibit branching defects and fail to 
generate a gas-filled lumen (B-B’’).  Dashed lines represent proximal end of cell. (C) 
Branching was quantified by designating branches of terminal cells as primary (green), 
secondary (red), tertiary (blue), or quaternary branch and totaling all branches.  Tertiary 
and quaternary branching is affected in Zpr1 mutants.  Error bars are ±2 S.E.M of each 
class (n=9).  (D) Mapping and identification of 31ZZ mutant.  Genetic map of the X 
chromosome and the ct-v interval.  A combination of visible markers and single 
nucleotide polymorphisms were used to map the lethality associated with 31ZZ to a 72 kb 
interval.  Black and white boxes represent individual genes within the region. Subsequent 
sequencing of genes in the region identified a single A to T transversion at base pair 
position 172 of the Zpr1 coding sequence. Zpr1 coding region represented by black 
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Figure 3.2:  EGFR loss-of-function phenocopies Zpr1 mutants.  (A) Homozygous 
mutant cells are marked by the expression of GFP.  (B) Tracheal specific expression of 
EGFR-RNAi (Bloomington 25781) (B) and dominant negative EGFR (C).  Tracheal cell 
branching patterns and air-filled lumens are characterized by using GFP (A, B and C) and 
brightfield microscopy (A’, B’ and C’).  EGFRflb2 loss-of-function homozygous mutants 
display a lumenless phenotype (A-A’).  Depletion of EGFR by RNAi results in gas-filling 
defect (B-B’).  Expression of a dominant negative form of the EGFR also results gas-
filling defect (C-C’).  (D) Quantification of pentrance of EGFR lumenless phenotype.  
For all conditions quantified a minimum of 55 cells were scored.  For all RNAi and DN 
experiments terminal cells in the third and fourth metameres of single animals were 
































































































































































































Figure 3.3:  Zpr1 is epistatic to both EGFR and FGFR signaling in terminal cells. 
The tracheal specific btl promoter is used to positively label Zpr1 homozygous mutant 
cells through the expression of a UAS-DsRed transgene and simultaneously drive the 
expression of other transgenes.  Tracheal cell branching patterns and air-filled lumens are 
characterized by using DsRed (A-F) and brightfield microscopy (A’-F’).  Over-
expression the wild-type form of the EGF receptor in terminal cells is sufficient to drive 
luminal overgrowth (A-A’).  Over-expression of an activated form of the EGF receptor in 
wild-type terminal cells results in extensive overgrowth of lumens and defects in 
branching (B-B’).  Over-expression of an activated form of the FGF receptor in wild-type 
terminal cells results in extensive overgrowth of lumens and defects in branching (C-C’).  
Zpr1 mutants are epistatic to the extensive luminal growth caused by wild-type EGFR 
overexpression (D-D’) and activated EGFR (E-E’).  Zpr1 mutants are epistatic to the 
extensive luminal growth caused seen in λblt (FGFR) overexpression (F-F’) 














































Figure 3.4:  Model of Zpr1 function downstream of both EGFR and FGFR signaling 
in terminal cells.  FGF signaling is required for early outgrowth and branching, and EGF 
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 In a forward genetic screen of the X chromosome for mutations disrupting 
different aspects of branching and lumen formation in Drosophila tracheal terminal cells,  
mutations in the gene Zpr1 (zinc-finger protein 1) were identified by their primary effect 
on lumenogenesis.  Zpr1 is an evolutionarily conserved protein characterized by two C4 
zinc fingers and two conserved homology domains.  In mammals, Zpr1 was first 
identified as a cytoplasmic protein that was capable of binding the intracellular domain of 
the unactivated EGF receptor (Galcheva-Gargova et al., 1996).  Upon EGFR activation 
the EGFR-Zpr1 complex dissociates and Zpr1 can interact with the eukaryotic translation 
elongation factor 1A (eEf1α) (Gangwani et al., 1998) or bind multiprotein complexes 
formed by the survival motor neurons 1 (SMN1) protein (Gangwani et al., 2005).  The 
significance of these interactions remains unclear but are thought in part to help localize 
Zpr1 to the nucleus.  
The effect of active EGF signaling on the subcellular localization of Zpr1 
suggests that there may be factors that can negatively regulate this interaction.  Recent 
evidence has shown that the receptor tyrosine phosphatases, Ptp4E and Ptp10D (the only 
two phosphatases known to be expressed in tracheal system) play a role in regulating 
 
  56 
tracheal lumen formation during Drosophila embryogenesis (Jeon and Zinn, 2009).  
Additional experiments have shown that these RPTPs may exert this control through the 
negative regulation of the EGFR (Jeon and Zinn, 2009).  Here we show that terminal 
cells homozygous mutant for both Ptp4E and Ptp10D display extensive cytoplasmic 
outgrowth and blebbing, but fail to generate a gas-filled lumen or display luminal 
overgrowth in our gas-filling assay.  We also show that RNAi knockdown of the two 
known Zpr1 binding partners eEf1α and SMN1 also result in lumenless terminal cells.  
 
Materials and methods 
Recombination of PTP mutants onto FRT19A chromosome 
Trans-heterozygous females containing a chromosome bearing mutations in 
Ptp4E and Ptp10D (the double mutant will be referred to as Ptp4E10D ) over a multiply 
marked X chromosome (FRT19A) were crossed and progeny reared on G418 selection 
media.  This allowed us to select recombination events in which the FRT19A chromosome 
had been included (Figure 4.1).  Single viable females with the visible markers indicating 
that a recombination event had occurred within our interval of interest were used to 
establish individual balanced lines.  These lines were then tested for lethality and 
subsequently used in MARCM (Lee and Luo, 1999) to test the function of Ptp4E10D in 
tracheal terminal cells. 
 
RNAi knockdown of known Zpr1 interacting proteins 
The tracheal specific promoter breathless (Shiga et al., 1996) was used to drive 
UAS-RNAi transgenes directed against individual Zpr1-binding partners.  Expression of 
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GFP was used to assay terminal cell branching and brightfield microscopy for gas-filling 
defects.  Lethality was assayed by using the Actin-promoter to ubiquitously drive the 
expression of GAL4 mediated-RNAi knockdown.  Individual fly lines used for RNAi 
experiments are listed in Table 4.1.  
 
Molecular cloning and generation of UAS-Zpr1-RNAi  
transgenic flies 
To generate a Zpr1-RNAi targeting construct we used the primer pairs Zpr1RNAi 
A and Zpr1RNAi B (Table 4.2) to generate 448bp amplicons of the Zpr1 coding 
sequence (Table 4.2).  We then inserted each of these these amplicons in a reverse 
tandem orientation into a pUAST+I (a gift from Amin Ghabrial) by using the 
NotI/KpnI/KpnI/XbaI cloning sites in the vector.  The construct was then injected into 
Drosophila embryos to generate transgenic flies.  All injections were performed by 
Genetic Services Inc.   
 
Molecular cloning and generation of UAS-Zpr1 site-directed mutants 
To generate UAS-Zpr1 constructs harboring previously characterized point 
mutations, we used a standard PCR-based zippering cloning technique in which point 
mutations are introduced via custom oligonucleotide primers.  Primer pairs ZR303FN, 
ZR303R, ZR407FN and ZR407R  (Table 4.2) were used for the PCR amplification of 
individual products with overhangs.  Primers ZprOUTF and ZprOUTR were then used 
for the final zippering reaction (Table 4.2).  Targeting vectors were injected in embryos 
harboring the VK0027 site for specific integration (Venkken et al., 2006). 
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Ultrastructural analysis of mutant terminal cells 
The tracheal specific promoter breathless was used to drive either a UAS-RNAi 
transgene directed against Zpr1 or various EGFR and FGFR over-expression transgenes 
(Table 4.3). For our experiment we used larvae at stage L1 and L2 because of their small 
size.  Larvae were picked at late L1 and early L2 larval stages and kept in PBS buffer 
before freezing.  Animals were then prepared by using a method developed by L. 
Nikolova in our lab.  Briefly, larvae were loaded into the specimen carriers filled with the 
bacteria E. coli, which was used as cryo-protectant.  Carriers were then high pressure-
frozen using a BAL-TEC HPM 010 freezer (BAL-TEC, Inc., Carlsbad, CA).  Larvae 
were then submitted to a freeze substitution in a pre-cooled to -90°C mix of 1-2% 
osmium tetroxide (OsO4) and 0.1% Uranyl Acetate in 97% acetone using Leica EM AFS 
(Leica Microsystems, Vienna, Austria.  Specimens were freeze substituted for 72 hrs at -
90°C, then gradually warmed up at the rate of 5°C/hrs to -20°C and incubated at this 
temperature for another 8-16 hrs.  Specimens were then rinsed with pure acetone.  
Specimen infiltration was performed by incubating the specimens in a gradually 
increasing concentrations of Epon Araldite epoxy resin (EMS cat. 13940) and then 
prepared for polymerization at 60°C for 48 hrs.  45-70nm sections were obtained using a 
diamond knife and collected on coated copper grids.  The sections were imaged at 






Molecular cloning and generation of fluorescent  
tagged Zpr1 transgenic flies 
To generate fluorescent tagged Zpr1 constructs we used multiple approaches.  
First, we made two genomic rescue constructs in which we fused the coding sequence of 
either eGFP or mCherry (Promega) to the N-terminus end of Zpr1.  To achieve this, we 
inserted a KpnI restriction enzyme site before the translational start of Zpr1 using primers 
Zpr1NtermF, Zpr1NtermR, GAPIF and GAPJ3R (Table 4.2).  We then inserted the 
coding sequence of either eGFP or mCherry into this KpnI site with standard cloning 
techniques.  We inserted this genomic construct into the p[ACMAN] transformation 
vector (Venkken, et al.,  2006) for injection and site-specific integration into the 
VK00027 genomic locus.  Additionally, we generated a UAS-Zpr1 construct in which the 
coding sequence of eGFP was inserted at the C-terminus of Zpr1.  To do this, we first 
amplified the coding regions of both Zpr1 and GFP with primers eGFP ForwardZPR1, 
Zpr1RevGFP, Zpr1cDNAF and Zpr1cDNAR (Table 4.2).  These PCR products were 
designed to have overhangs that could then be used to zipper the two products together in 
a subsequent round of PCR.  We then cloned the zippered product into a pUAST+attB 
targeting construct (a gift from Carl Thummel) by using the NotI and StuI sites in the 
plasmid.  This targeting construct was then injected for site-specific integration into both 
the VK00027 and ATTP16 genomic loci.  All injections were performed by Genetic 






Clonal analysis of PTP double mutants 
Mutants homozygous null for the two receptor tyrosine phosphatases expressed in 
the tracheal system are embryonic lethal (Jeon and Zinn, 2009).  To bypass the lethality 
and assay the effect of these homozygous mutations specifically in tracheal terminal cells 
we recombined the Ptp4E10D mutations onto our FRT19A chromosome and performed 
clonal analysis using the MARCM system (Figure 4.1).  Twenty individual lines were 
established from the general recombination scheme outlined in Figure 4.1 and tested for 
lethality.  Of these 20 lines, 6 lines tested were viable indicating that we had lost one of 
the RPTP mutations and were and discarded.  These numbers are consistent with the 
relative positions of the genetic markers used.  Of the remaining 14 lethal lines (which 
contained both RPTP mutations), 7 were used for clonal analysis and all but one 
displayed a cystic blebbing phenotype or uncontrolled cytoplasmic growth (Figure 4.2).  
Contrary to our model in which loss of RPTP function would result in an unregulated 
luminal growth, all homozygous mutant cells scored were unable to generate gas-filled 
lumens.  Interestingly, all of the lumenless cells also displayed varying degrees of 
cytoplasmic blebbing and outgrowth.  One interpretation of this result would be that these 
RPTPs are simply involved in cytoplasmic growth and not in a lumenogenesis pathway.  
Another interpretation may be that RPTPs are involved in the regulation of both a 
cytoplasmic outgrowth program and a lumenogenesis program, but the continued 
cytoplasmic growth may remove important cues that are necessary for specifying where a 
cell will make a lumen thus impeding general lumenogenesis.   
 
  61 
Generation of a Zpr1 RNAi transgenic line 
The tracheal specific promoter breathless was used to drive a UAS-RNAi 
transgene directed against Zpr1 (V12665).  This transgenic line was obtained from the 
Vienna Drosophila RNAi Center (VDRC) and used to assay for terminal cell defects and 
lethality.  Lethality was assayed by using the Actin-promoter to ubiquitously drive the 
expression of GAL4 mediated-RNAi knockdown.  We failed to induce either lethality or 
see a lumenless phenotype in our RNAi experiment.  Since we knew that a null 31ZZ 
mutant displayed both lethality and mutant terminal cells that failed to fill with gas, we 
concluded that this RNAi targeting construct was ineffective.  We thus generated a new 
Zpr1-RNAi construct (See Materials and Methods) and found that expression in terminal 
cells led to ∼60% of cells displaying a lumenless phenotype (Figure 4.3).  Although this 
result indicates that the targeting construct is better able to functionally knock-down Zpr1 
in terminal cells when compared to the VDRC line, the low efficiency may prohibit its 
use in tissue-specific experiments. 
 
RNAi knockdown of known Zpr1 interacting proteins 
To better understand the molecular pathway through which Zpr1 mediates lumen 
formation in tracheal terminal cells, we tested the requirement of the known Zpr1 
interacting proteins by RNAi.  Previous evidence has shown that mammalian Zpr1 can 
interact with the eukaryotic translation elongation factor 1A (eEf1α) and form 
multiprotein complexes with the survival motor neurons 1 (SMN1) protein (Gangwani et 
al., 1998; Gangwani et al., 2005).  Additionally, it has been shown that both of these 
binding events result in the nuclear redistribution of Zpr1-containing complexes, and the 
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disruption of these interactions affects cell growth (Gangwani, 2006).  Although these 
interactions clearly play a role in mediating growth, the molecular mechanism through 
which they exert this control remains uncharacterized. 
  Drosophila contains a single homologue (smn) of the human SMN1 gene which 
was identified by its sequence homology to the human gene.  In humans, SMN1 has 
undergone a duplication event which has resulted in two copies of the SMN1 gene (SMN1 
and SMN2).  Mutations in the SMN1 locus are viable because of the partial redundancy 
conferred by SMN2.  In contrast to the human SMN1 mutant phenotype, mutations in 
Drosophila smn cause embryonic lethality.  To test the requirement of smn in tracheal 
terminal cells, we obtained transgenic flies carrying different RNAi constructs directed at 
smn.  To assay for RNAi function we first crossed each line to the ubiquitous Actin-GAL4 
driver and found that only one of the three lines displayed a lethal phenotype.  We then 
used the btl-GAL4 driver to express these RNAi transgenes specifically in the tracheal 
system.  We found of the three lines tested, tracheal cells in one line (K16725R-2) 
phenocopied Zpr1 null mutants and displayed a lumenless phenotype (Figure 4.3).  The 
line that displayed a lumenless phenotype is also the only line that caused lethality when 
driven by the Actin-GAL4 promoter.  This data indicates that that the lack of a lumenless 
phenotype may arise from inefficient knockdown in the two remaining lines.   
The binding interaction between Zpr1 and eEf1α was first indentified and 
characterized in mammalian cell lines and the yeast Saccharomyces cerevisiae.  These 
studies showed that Zpr1 and eEf1α bind one another and redistribute to the nucleus in 
response to nutrient stimulation (Gangwani et al., 1998).  This interaction has been shown 
to be important for growth in both yeast and mammalian cell lines, since disruption of 
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this interaction results in cell cycle arrest and defective cell growth (Gangwani, 2006).  
Previous studies have shown that eEf1α is involved in diverse cellular processes, but a 
specific role or molecular mechanism for its interaction with Zpr1 has not been identified 
(Munshi et al., 2001; Newberry et al., 2007).  Drosophila contains two eEf1α 
homologues (eEf1α100E and eEf1α48D).  To assay the specific requirement of eEf1α in 
tracheal terminal cells, we used the tracheal specific promoter btl to drive RNAi 
constructs targeting these genes.  We obtained a total of five transgenic lines targeting 
both eEf1α100E or eEf1α48D (the similarity between both of these genes makes 
targeting each gene individually difficult).  All five transgenic lines caused a lumenless 
defect in tracheal terminal cells.  These data indicate that disruption of either of the 
previously identified Zpr1 binding partners results in lumenless terminal cells.     
The observation that Zpr1 re-localizes from the cytoplasm to the nucleus during 
active signaling has led to the idea that Zpr1 must play an important role in the nucleus.  
Recently it was discovered that in yeast, the peptidyl-prolyl isomerase Cyclophilin A 
(CprA) promotes the export of Zpr1 from the nucleus (Ansari et al., 2002).  In 
Drosophila there is a single Cyclophilin A homologue named cyp1.  We hypothesized 
that if Zpr1’s primary role in promoting lumenogenesis was in the nucleus, then if we 
could inhibit the action of its nuclear exporter cyp1, we could sequester Zpr1 in the 
nucleus and see an overgrown lumen phenotype.  To perform this experiment we 
obtained two transgenic lines with RNAi constructs targeting cyp1.  We used both the 
ubiquitous Actin-GAL4 promoter and the tracheal specific btl-Gal4 promoter to 
individually drive the expression of both of these RNAi transgenes and but did not 
observe either a lethal phenotype or abnormal tracheal development (data not shown).  
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One simple interpretation of these experiments could be that the extent of cyp1 
knockdown was insufficient to sequester Zpr1 in the nucleus resulting in a wild-type 
phenotype.  Another possibility is that in Drosophila, Zpr1 nucelar export may be 
mediated by a different protein, or multiple redundant proteins.  One final interpretation 
of these experiments could be that the role of Zpr1 in lumen formation is mainly 
cytoplasmic and the inhibition of its nuclear export may not have an effect on 
lumenogenesis.   
 
Molecular cloning and generation of UAS-Zpr1 site directed mutants 
The initial identification of CprA as the protein responsible for Zpr1 nuclear 
export in yeast also identified point mutations in the yeast Zpr1 that disrupted this 
CprA/Zpr1 interaction (Ansari et al., 2002).  Independent point mutations resulting in a 
glycine to aspartic acid change (amino acid position 337) and aspartic acid to asparagine 
(amino acid position 444) were identified in a screen aimed at identifying mutations that 
could induce synthetic lethality when placed in a CypA null mutant background (Ansari 
et al., 2002)).  Both mutations resulted in the constitutive nuclear localization of mutant 
Zpr1 proteins.  To investigate the significance of these point mutants in Drosophila 
tracheal terminal cell development we generated the corresponding point mutations in 
Drosophila UAS-Zpr1 constructs (amino acid residues 303 and 407 respectively).  We 
first tested whether expression of either of these Zpr1 point-mutant constructs displayed 
dominant phenotypes by using the btl-Gal4 to drive their expression.  We find that 
neither of these transgenes have dominant effects when overexpressed in tracheal 
terminal cells.  We next tested whether either of these transgenes were able to rescue the 
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loss of Zpr1.  To do this we made Zpr1 MARCM mosaics in which the btl-GAL4 which 
positively marks mutant cells also drives the expression of the mutant UAS-Zpr1 
transgene.  We find that expression of either of these mutant transgenes is not sufficient 
to rescue the lumenless phenotype of a Zpr1 homozygous mutant terminal cell (data not 
shown).  Note, we have shown that expression of a wild-type Zpr1 in terminal cells is 
sufficient to rescue Zpr1 null mutant. 
 
Ultrastructural analysis of mutant terminal cells 
We have previously shown that overexpression of the wild-type version of the 
EGFR results in an increase in lumen formation.  In addition, overexpression of an 
activated form of the receptor exacerbates this extensive luminal overgrowth defect.  
However, the extent of luminal growth in both of these phenotypes is difficult to 
characterize with brightfield optics.  To characterize the extensive luminal growth 
observed upon overexpression of either wild-type or activated forms of the receptor, we 
prepared larvae expressing these constructs for ultrastructural analysis by electron 
microscopy.  Wild-type tracheal terminal cells have a single lumen which can be readily 
identified by its dark staining taenidial folds, a modification of the chitinous exoskeleton 
found in insect trachea (Figure 4.4).  However, we found that overexpression of the wild-
type EGFR results in terminal cells that have at least one additional air-filled luminal 
structure observed in each cross-section.  Similarly, we find that overexpression of 
activated EGFR results in the creation of multiple luminal structures.  To assay what a 
functionally lumenless terminal cell looks like by ultrastructural analysis, we prepared 
animals expressing our UAS-Zpr1-RNAi transgene.  We find that in the case of Zpr1 
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knockdown, terminal cells are able to create what structurally appears to be a wild-type 
lumen with the exception that these lumens have dark staining material where wild-type 
cells have empty space (Figure 4.4) .  This data may indicate that the role of Zpr1 occurs 
late in the lumenogenesis pathway.  Another interpretation of this data is that the 
ultrastructural phenotype we see in Zpr1-RNAi cells is representative of a hypomorphic 
allele of Zpr1 and that the null mutant would appear more severe.  
 
Molecular cloning and generation of fluorescent tagged Zpr1  
transgenic flies 
To investigate the subcellular localization and tissue specific requirements of 
Zpr1, we generated a series of fluorescent tagged Zpr1 constructs.  First, we made a 
genomic rescue construct in which we fused the coding sequence of either eGFP or 
mCherry to the N-terminus of Zpr1.  Both of these constructs were able to fully rescue 
the lethality associated with Zpr1 mutants(data not shown) as well as the lumenless 
defect in homozygous mutant terminal cells (Figure 4.5).  We then used fluorescence 
microscopy to visualize tissues expressing these genomic tagged versions of Zpr1.  
Unfortunately, we were unable to detect the fluorescence from either construct.  Previous 
expression data for Zpr1 indicates that maternally deposited in the embryo and is widely 
expressed throughout embryogenesis (FlyAtlas).  The lack of fluorescence from both of 
these constructs may indicate a very low level of expression of Zpr1 throughout larva.  
To assay the subcellular localization of Zpr1 in tracheal terminal cells we constructed a 
UAS-Zpr1 transgene with a C-terminus eGFP tag.  To test whether loss of Zpr1 could be 
rescued by this UAS-Zpr1-GFP transgene we made Zpr1 MARCM mosaics in which the 
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btl-GAL4 that positively marks mutant cells also drives the expression of the UAS-Zpr1-
GFP transgene.  We find that expression of this transgene is sufficient to rescue the 
lumenless defect in Zpr1 homozygous mutant terminal cells (Figure 4.6).  We then 
employed this UAS-Zpr1-GFP transgene to visualize the subcellular localization of Zpr1 
in the presence of wild-type Zpr1.  For all cells scored, GFP expression seemed to be 
enriched in the nucleus when compared to a DsRed transgene expressed in the same cell 
(Figure 4.7).  This UAS-Zpr1-GFP transgene can be used in future experiments to 




Zpr1 is an evolutionarily conserved protein that was initially identified by its 
ability to bind the intracellular tail of the unactivated EGFR.  Subsequent analysis 
showed that, in response to EGFR stimulation, Zpr1 accumulates in the nucleus.  The 
lack of a nuclear localization sequence on Zpr1 led to the finding that both the eukaryotic 
translation elongation factor 1A (eEf1α) and the survival motor neurons 1 (SMN1) 
protein could bind Zpr1, and form multiprotein complexes that localize to the nucleus of 
proliferating cells.  A previously conducted forward genetic screen for mutations 
affecting Drosophila terminal cell development identified mutations in Zpr1 by their 
primary effect on lumen formation.   We show here that the disruption of the two 
previously identified binding partners of Zpr1 also results in lumenless terminal cells.  
Additionally we show that the null mutations in the two RPTPs expressed in tracheal 
system result in excessive cytoplasmic outgrowth and lumenless cells.  This result on its 
own may be interpreted as an indication that these RPTPs are not very specific and may 
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be affecting other RTKs. But, when these data are taken together with our genetic data 
showing that multiple RTKs may be feeding into the Zpr1 pathway, a more complex 
signaling cascade arises.  Indeed, the idea that FGFR may be playing a role in the Zpr1 
cascade has been tested indirectly by using mutations affecting smn.  Specifically, Sen et 
al., showed that tissue specific activation of the FGF pathway ameliorates smn defects in 
Drosophila muscle.  Although the downstream targets of this rescue were not 
investigated, it supports the hypothesis that over-activation of Zpr1 may be sufficient to 
bypass mutations in smn.  We have now generated some of the tools that will allow us to 


























Table 4.1. RNAi knock-down of Zpr1 interacting proteins 
 
Gene CG Number Stock Number Lethality     
Tracheal 
Defect  
SMN1 CG16725 K16725R-2* Yes Lumenless 
 CG16725 K16725R-3* No WT 
 CG16725 BL45447 No WT 
eEF1A100E CG1873 V40157† Yes Lumenless 
 CG1873 V40156† Yes Lumenless 
 CG1873 K1873R-4(3)* Yes Lumenless 
eEF1A48D CG8280 V24271† Yes Lumenless 
 CG8280 V49890† No Lumenless 
Zpr1 CG9060 V12665† No No 
 CG9060 R284 Yes Lumenless 
Cyp1 CG9916 BL33001 No WT 
 CG9916 BL33950 No WT 
 
*Drosophila Genetic Resource Center 
†Vienna Drosophila RNAi Center 
BL- Bloomington Stock center 












Table 4.2. List of primer sequences used for generating transgenic constructs.   
 
Primer name Sequence Purpose     
Zpr1RNAiA 



























mCherryF AGGTACCATGGTGAGCAAGGGCGAGGAGGATAAC mCherry 

















ZR303FN GACGAACGAAGTGAAGTCCGACGGCGGAGTGGAGGCGCAGGGT QCR303 
ZR303R GTCGGACTTCACTTCGTTCGTCTT QCR303 
ZR407FN ATTACGCTGGTGCTGGAGACCCCGGCCGGTAATACCTATGTGCAA QCR407 
ZR407R GGTCTCCAGCACCAGCGTAATGACTCG QCR407 
ZPROUTF ATGTCCACCGTGAGCGACCCCAACA QC 





Table 4.3. Transgenic fly lines used for ultrastructural analysis. 
 










EGFR CG10079 BL9533 Activated 
Extra 
Lumens 



















































Figure 4.2. Homozygous PTP mutant terminal cells display cytoplasmic blebbing 
and fail to fill with gas. 
Moscaic L3 larvae were generated using the MARCM system.  Homozygous mutant cells 
are positively marked by the expression of GFP through the tracheal specific btl 
promoter.  Tracheal cell branching and gas-filling patterns are characterized by using 
GFP (A) and brightfield microscopy (A’), respectively.  Dashed lines represent the 




































Figure 4.3. RNAi knockdown of Zpr1 and known binding proteins. 
The tracheal specific btl promoter is was used to express dsRNA against Zpr1 and known 
interacting proteins.  Tracheal cell branching and gas-filling patterns are characterized by 
using GFP (A, B and C) and brightfield microscopy (A’, B’, and C’), respectively.  Bars:  




































Figure 4.4. Ultrastructural analysis of EGFR overexpression and knockdown of 
Zpr1. 
To characterize the structures of luminal overgrowth and lumenless phenotypes, larvae 
expressing different UAS transgenes with the tracheal specific btl promoter were 
prepared for analysis by electron microscopy.  Tracheal terminal cell lumens are 
visualized by EM (A, B, C, and D).  Arrows indicate lumen structures. Bars:  200nm (A) 



















































Figure 4.5. Genomic N-terminus GFP tagged Zpr1 rescue of Zpr131ZZ mutant cells.  
Moscaic L3 larvae were generated using the MARCM system.  A single copy of the 
genomic N-terminus GFP tagged Zpr1 is in the background of the heterozygous animal. 
Tracheal cell branching and gas-filling patterns are characterized by using DsRed (A) and 



















































Figure 4.6. UAS-C-terminus GFP tagged Zpr1 rescue of Zpr131ZZ mutant cells.  
Moscaic L3 larvae were generated using the MARCM system.  The tracheal specific btl 
promoter is used to positively label Zpr1 homozygous mutant cells through the 
expression of a UAS-DsRed and simultaneously drive the expression of a C-terminus 
tagged Zpr1-GFP transgene.  Tracheal cell branching patterns and air-filled lumens are 




































Figure 4.7. UAS-C-terminus GFP tagged Zpr1 localization in wild-type terminal 
cells. 
The tracheal specific btl promoter is used to dirve the expression of DsRed and a UAS-C-
terminus GFP tagged Zpr1 transgene.  The subcellular localization of a DsRed transgene 
(A and A’) can be used to compare to the localization of GFP tagged-Zpr1 construct (B 
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MUTATIONS IN 2 DISTINCT GENETIC PATHWAYS RESULT IN  
 
CEREBRAL CAVERNOUS MALFORMATIONS  
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Metzstein MM, Whitehead KJ, Li DY (2011).  Mutations in 2 distinct genetic pathways 
result in cerebral cavernous malformations in mice. J. Clin. Invest. 121:1871–1881. 
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Cerebral cavernous malformations (CCMs) are a common type of vascular malformation in the brain that 
are a major cause of hemorrhagic stroke. This condition has been independently linked to 3 separate genes: 
Krev1 interaction trapped (KRIT1), Cerebral cavernous malformation 2 (CCM2), and Programmed cell death 
10 (PDCD10). Despite the commonality in disease pathology caused by mutations in these 3 genes, we found 
that the loss of Pdcd10 results in significantly different developmental, cell biological, and signaling pheno-
types from those seen in the absence of Ccm2 and Krit1. PDCD10 bound to germinal center kinase III (GCKIII) 
family members, a subset of serine-threonine kinases, and facilitated lumen formation by endothelial cells 
both in vivo and in vitro. These findings suggest that CCM may be a common tissue manifestation of distinct 
mechanistic pathways. Nevertheless, loss of heterozygosity (LOH) for either Pdcd10 or Ccm2 resulted in CCMs 
in mice. The murine phenotype induced by loss of either protein reproduced all of the key clinical features 
observed in human patients with CCM, as determined by direct comparison with genotype-specific human sur-
gical specimens. These results suggest that CCM may be more effectively treated by directing therapies based 
on the underlying genetic mutation rather than treating the condition as a single clinical entity.
????????????
Cerebral cavernous malformations (CCMs) are common vascular 
malformations with a prevalence of 1 in 200 to 250 individuals in 
unselected populations (1, 2). CCMs can lead to focal neurologi-
cal deficits, seizures, and hemorrhagic stroke, but no pharma-
cologic therapy currently exists (3). CCMs predominantly occur 
in the central nervous system and are characterized by subclini-
cal bleeding and consequential hemosiderin deposits that are 
detected by MRI (4). MRI is the primary clinical modality for 
detection, diagnosis, and management of CCMs. Hemosiderin 
deposits give CCMs an MRI appearance of a central mass with 
a dark perilesional halo, whose appearance is nearly diagnostic 
(pathognomonic) of cavernous malformation (5). Cavernous 
malformations are characterized by a complex of vascular chan-
nels of varying sizes lined by a single layer of endothelial cells 
without any abnormally large arteries, arterialized veins, or large 
venous outflow vessels. Although dense fibrillary neuroglial 
tissue may penetrate the mass, vascular channels are generally 
arranged in a back-to-back pattern with little or no intervening 
brain parenchyma. There is often a peripheral margin of gliotic 
tissue containing hemosiderin-laden macrophages (6).
CCMs can occur sporadically or be inherited in an autosomal 
dominant pattern. Familial CCM has been linked to heterozygos-
ity for any of 3 genes: Krev1 interaction trapped (KRIT1), Cerebral 
cavernous malformation 2 (CCM2), and Programmed cell death 
10 (PDCD10) (7). All 3 proteins bind each other in coimmuno-
precipitation experiments on cells overexpressing these proteins, 
leading to the hypothesis that they function as a complex to affect 
a common signaling mechanism (8). Both Krit1 and Ccm2 are 
required for proper connection of the developing heart with the 
aorta to establish circulation in the mouse embryo (9, 10). Mice 
lacking either Krit1 or Ccm2 fail to form a lumenized first bran-
chial arch artery to link the heart and aorta; as a result, mice lack-
ing either gene die at the same age. The requirement for Ccm2 is 
endothelial autonomous (9, 11). In the endothelium, both KRIT1 
and CCM2 suppress the activity of the small GTPase RhoA (9, 
12). Loss of either gene leads to RhoA activation and signaling 
through Rho kinase (ROCK) resulting in increased actin stress 
fibers, impaired cell-cell interactions, and increased vascular per-
meability (9, 12, 13). These defects can be reversed in cell culture 
and in mice with inhibitors of RhoA including HMG-CoA reduc-
tase inhibitors (statins) (9, 12).
A recent report suggested a similar mechanism of Rho activation 
for PDCD10 (14). However, other studies have suggested a different 
cell-signaling role for PDCD10. While KRIT1, CCM2, and PDCD10 
all occupy the cytoplasmic compartment of the cell, unique sub-
cellular localization for each has been described, including nuclear 
localization of KRIT1 (15) and Golgi localization of PDCD10 (16). 
Each protein has also been found to have unique binding partners 
(17–19). PDCD10’s binding partners include members of the germi-
nal center kinase III (GCKIII) subfamily of serine-threonine kinas-
es with homology to yeast sterile-20 (STE20) kinase (16, 20–23). 
Furthermore, the clinical features of CCM in KRIT1, CCM2, and 
PDCD10 families have important differences (24, 25), with PDCD10 
resulting in the most severe disease (24, 26). It is possible that CCM 
disease is the common result of multiple unique mechanisms and 
may require unique therapeutic strategies to target the underlying 
disturbed cellular and signaling pathways.
Conflict of interest: The University of Utah seeks to commercialize this technology 
and has filed patent applications related to this manuscript.




???? The Journal of Clinical Investigation   http://www.jci.org   Volume 121   Number 5   May 2011
Though the signaling and cellular mechanisms associated with 
the 3 known CCM proteins may be different, a common genetic 
mechanism of loss of heterozygosity (LOH) has been suggested 
for familial CCM disease (27–29). Familial CCM is more aggressive 
than sporadic disease, with an earlier age of onset, increased risk 
of hemorrhage and seizure, and an increased number of lesions (3, 
30–32). These observations have led to the hypothesis that CCM 
disease occurs by the Knudson 2-hit mechanism, similar to retino-
blastoma (33). There is limited evidence from human pathologic 
specimens to support an association of LOH with CCM lesions. 
In a series of challenging experiments, a number of investigators 
have identified biallelic mutations, 1 somatic and 1 germline, in 
the endothelium of a subset of patient samples (27, 28, 34). While 
LOH could not be confirmed for a number of samples, a total of 
4 cases have been described for KRIT1 and 1 case each for CCM2 
and PDCD10. Mice heterozygous for Krit1 or Ccm2 do not develop 
cavernous malformations, and no examples of secondary somatic 
mutations have been reported (35, 36).
To determine whether endothelial LOH is not simply associ-
ated with, but is causative for, CCM pathology, requires an animal 
model with a controlled genetic mutation that can be directed and 
detected in a tissue-specific manner. In this work, we use drug-
inducible, tissue-specific strains of Cre recombinase to target 
conditional null alleles of the CCM genes to test directly the 2-hit 
hypothesis for cavernous malformations. We demonstrate that 
Pdcd10 differs substantially from Ccm2 in development, cell biol-
ogy, and signaling, yet LOH is the common genetic mechanism 
to cause CCMs in both genotypes. These findings suggest that 
PDCD10 influences different endothelial signaling pathways from 
KRIT1/CCM2 to lead to a common histopathology and imply that 
medical treatment to stabilize familial CCM may need to be devel-
oped and evaluated in a genotype-specific manner.
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Loss of Pdcd10 results in embryonic lethal phenotypes distinct from loss of 
Krit1 or Ccm2. To determine the role of Pdcd10 in development and 
disease, we developed a conditional null allele, Pdcd10flox, in which 
exons 4–8 are flanked with LoxP sites (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI44393DS1). This strategy also allowed us to generate a consti-
tutive null allele, Pdcd10–, by crossing mice carrying Pdcd10flox with 
a mouse strain expressing Cre recombinase in the germline (37). 
To characterize the role of Pdcd10 in development, we intercrossed 
Pdcd10+/– mice and harvested embryos at varying stages of devel-
opment. Surprisingly, we found that mice lacking Pdcd10 died at 
a much earlier age than those deficient for either Krit1 or Ccm2. 
Whereas Krit1 and Ccm2 mice show growth arrest at E9.0 and die 
at E11 (9–11), the loss of Pdcd10 leads to growth arrest at E8.0, after 
gastrulation, but prior to the onset of circulation or the requirement 
for cardiovascular function (Table 1 and Supplemental Figure 1).
An earlier requirement for Pdcd10 than Krit1 or Ccm2 in devel-
opment does not preclude a shared role in the vascular system. 
Mice with endothelial loss of Ccm2 phenocopy the constitutive 
null mutant (9, 11), so we sought to determine whether mice with 
endothelial loss of Pdcd10 would also recapitulate the Ccm2 phe-
notype. Using the endothelial Tie2-Cre driver, the same Cre driver 
that we used to ablate Ccm2 (9), we found that although mice with 
endothelial loss of Pdcd10 (Pdcd10flox/–;Tie2-Cre) did not survive to 
birth, they had patent branchial arch arteries, a developed circula-
tory system, and were indistinguishable from control littermates at 
E9.5 (Supplemental Figure 2). Instead, we found that loss of Pdcd10 
in the endothelium leads to progressive enlargement of the cardi-
nal vein and other veins of the rostral embryo at E11.5 (Figure 1). 
Venous enlargement was not due to abnormal cardiac structure or 
function (Figure 1 and Supplemental Figure 2), nor were defects 
observed in arteries of the embryo (Figure 1 and Supplemental 
Figure 2). Death occurred due to hemorrhage from venous rup-
ture by E13.5 (Table 2). Additionally, mice with loss of Pdcd10 in 
neural and glial tissues induced by Nestin-Cre showed no vascular 
or any other obvious defects and were born alive (Supplemental 
Figure 2 and Supplemental Table 1). These observations suggest 
that Pdcd10 is required in the endothelium for control of venous 
size and integrity, yet Pdcd10 differs from Ccm2 in that it is not 
required for the establishment of circulation.
Loss of PDCD10 does not affect RhoA signaling but results in lumen for-
mation defects. To explore the role of PDCD10 in endothelial cells, 
we depleted PDCD10 in human dermal microvascular endothelial 
cells (HMVEC) with siRNA (Supplemental Figure 3). Whereas the 
loss of CCM2 leads to an increase in actin stress fibers as a result 
of RhoA activation (9, 12, 13) and phosphorylation of myosin light 
chain-2 by Rho kinase (Figure 2), we observed none of these indica-
tors of RhoA activation with the loss of PDCD10 (Figure 2). Thus, 
the role of PDCD10 in endothelial cell biology and signaling dif-
fers from that of CCM2.
Having found that PDCD10’s function in development differs 
from that of CCM2, we sought to identify defects associated with 
PDCD10 depletion in assays relevant to vascular development. 
PDCD10-depleted HUVECs showed defective function in a 3D 
angiogenesis assay. Endothelial cells plated in a collagen matrix 
spontaneously organize into complex multicellular capillary-like 
networks with lumens (38), but cells depleted of PDCD10 failed 
to organize themselves into a lumenized network (Supplemental 
Figure 4, A and B). We explored potential downstream signaling 
pathways using this assay. A growing body of evidence suggests 
that PDCD10 interacts with the GCKIII subfamily of serine-threo-
nine kinases (16, 21–23); we used siRNA to deplete cells of each of 
the subfamily members (Supplemental Figure 3). We observed no 
effect on lumen formation with the knockdown of STK25, STK24, 
or MST4 in HUVECs (Supplemental Figure 4C).
Pdcd10 functionally associates with GCKIII in lumen formation. Because 
the GCKIII family members may be functionally redundant, we 
sought to validate the importance of the PDCD10-GCKIII interac-
tion in vivo and in a simpler genetic model. We chose the fruit fly, 
Drosophila melanogaster, in which the GCKIII family is represented by 
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Early growth arrest and death in embryos lacking Pdcd10
Cross  Pdcd10+/– × Pdcd10+/–
Genotype Pdcd10+/+ Pdcd10+/– Pdcd10–/– Total litters
No. of progeny
E7.5 75 114 52 27
E8.0 9 13 0A 4
E8.5 27 45 0A 13
E9.0 1 5 0 1
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a single protein, GCKIII. This model avoids the complexity of human 
or mouse, which has 3 GCKIII kinases, or zebrafish, which has 2 
orthologs for Pdcd10, 2 orthologs for STK25, and single orthologs for 
STK24 and MST4 (23). Furthermore, the Drosophila genome contains 
a single ortholog of PDCD10, but no orthologs for KRIT1 or CCM2. 
Thus, Drosophila represents a simple model organism for studying 
Pdcd10-specific biology. To ensure that the biochemical interaction 
between PDCD10 and GCKIII was conserved in Drosophila, we per-
formed immunoprecipitation assays with the Drosophila proteins. 
Drosophila Pdcd10 binds to GCKIII (Supplemental Figure 4D) in a 
manner analogous to that of human, mouse, or zebrafish protein 
(21, 23). A human disease PDCD10 mutation exists, which deletes 
18 amino acids crucial for PDCD10-GCKIII binding (21). Removal 
of the analogous 18 amino acids from the Drosophila Pdcd10 protein 
abrogated binding to GCKIII (Supplemental Figure 4D).
Whereas Drosophila do not develop a vascular system, they do form 
a branched, lumenized network of tubes in the tracheal (respira-
tory) system. This epithelial network requires coordinated cell-cell 
interactions and specialized cell-cell junctions, 
analogous to the mammalian vascular system 
(39, 40). To determine the necessity of Pdcd10 
in developing fly tracheal tubes, we expressed a 
dsRNA directed against Pdcd10 (41) under the 
control of the tracheal-specific Breathless pro-
moter (42) using the GAL4-UAS system (43). 
We found that tracheal tubes lacking Pdcd10 
grow and branch normally, but fail to lumen-
ize and fill with air (Supplemental Figure 5), 
indicating that Pdcd10 is required for normal 
lumen formation in fly tracheal tubes as it is in 
human endothelial tubes. This effect is highly 
penetrant; nearly all dsRNA-expressing flies 
show lack of lumenization in multiple tracheal tubes 
(Supplemental Figure 4E). The specificity of this effect 
is confirmed, as it could be rescued by coexpression 
of Drosophila Pdcd10 in RNAi-expressing cells (Sup-
plemental Figure 4E). Notably, coexpression of the 
18–amino acid deletion form of Drosophila Pdcd10, 
which does not bind to GCKIII, fails to rescue this phe-
notype (Supplemental Figure 4E). We used the same 
RNAi strategy to inactivate GCKIII (44) in the devel-
oping tracheal system. Tracheal tubes lacking GCKIII 
exhibit failure of lumenization (Supplemental Figure 5), 
and the phenotype appears very similar to that of 
Pdcd10-deficient tubes. Thus, Pdcd10 is essential for normal lumen 
formation in the absence of Krit1 and Ccm2 and in a manner that 
requires interaction with GCKIII kinases.
Our experiments in Drosophila suggested that GCKIII kinases 
are required for lumen formation but that functional redundancy 
in mammalian cells may have accounted for the lack of a lumen 
formation defect when any single kinase was lost. We therefore 
performed combinatorial knockdown experiments for pairs of the 
GCKIII kinases. Consistent with our hypothesis, we found that the 
loss of STK25, if coupled with the loss of either STK24 or MST4, 
was sufficient to reproduce the lumen formation defects seen with 
PDCD10 depletion (Supplemental Figure 4). Thus, PDCD10 inter-
action with GCKIII kinases is critical in lumen formation.
LOH of either Pdcd10 or Ccm2 causes murine cavernous malformations 
that phenocopy human CCMs. Pdcd10 and Ccm2’s functions clearly 
differ in embryonic development, in endothelial cell culture, and 
in signaling, and Pdcd10 is necessary for lumen formation in a 

















Loss of Pdcd10 in the endothelium leads to embryonic death after E12.5
Cross  Pdcd10flox/flox × Pdcd10+/–;Tie2-Cre
Genotype Pdcd10flox/+ Pdcd10flox/– Pdcd10flox/+;Tie2-Cre Pdcd10flox/–;Tie2-Cre
No. of progeny
E9.5 14 14 7 11
E12.5 13 28 16 16
E15.5 8 8 20 0
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to the same human disease. Limited human genetics suggested 
an association between LOH and CCM disease, so we investigated 
whether Pdcd10 and Ccm2 share this genetic mechanism for causing 
disease. To control the timing of the endothelial “second-hit,” we 
used a drug-inducible Cre strain under the control of the PDGF-B 
promoter. This PDGFb-iCreERT2 strain expresses a Cre recombinase 
activated only after administration of the drug tamoxifen. Con-
sistent with the original report describing this recombinase (37), 
we found that the administration of tamoxifen on the first post-
natal day (P1) led to efficient, endothelial-specific recombination 
throughout the entire brain vasculature (Supplemental Figure 6). 
The induction of endothelial LOH of either Pdcd10 or Ccm2 by this 
Cre at birth resulted in CCMs in mice as early as 1 month of age 
(Figure 3). Induction of endothelial LOH of either Pdcd10 or Ccm2 
resulted in a spectrum of vascular malformations, from capillary 
telangiectasias, to isolated caverns, to multiple back-to-back cav-
erns with thrombosis, hemorrhage, and formation of secondary 
channels (Supplemental Figure 7). Loss of protein product via 
LOH was confirmed by antibody staining (Supplemental Figure 8). 
The retinal vasculature is another location for human CCMs, and 
murine cavernous malformations were also observed in mouse ret-
inal vasculature (Supplemental Figure 9). To formally prove LOH 
in the endothelium of these CCMs, we performed laser capture 
microdissection to obtain tissue-specific DNA as previously done 
in human studies of CCM (28). We found that DNA from lesion 
endothelium had lost the conditional allele for either Pdcd10 or 
Ccm2, confirming LOH, whereas this allele could still be detected 
in adjacent neuronal tissue (Figure 3). In contrast, loss of Ccm2 in 
neural tissues using Nestin-Cre did not result in the development 
of vascular malformations (Supplemental Figure 10).
We characterized the histopathologic features of cavernous 
malformations in mice with induced endothelial loss of either 
Pdcd10 (Figure 4) or Ccm2 (Figure 5). We compared mouse CCMs 
with surgical specimens from CCM patients with germline muta-
tions of either PDCD10 (Figure 4) or CCM2 (Figure 5). Cavernous 
malformations in these induced mouse models share all of the 
key histologic features of CCM lesions with human specimens. 
Furthermore, both Pdcd10 and Ccm2 resulted in identical patho-
logic findings for all of these defining characteristics in both 
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vascular channels of variable diameter (Figure 4, A and B, and 
Figure 5, A and B), some of them with organized thrombi. 
Immunohistochemical stains for endothelium highlighted 
endothelial cells in the channels, with focal attenuation or loss 
of endothelial cells in larger channels (Figure 4, G and H, and 
Figure 5, G and H). Iron stain highlighted the presence of hemo-
siderin-laden macrophages and hemosiderin in the wall of the 
channels as well as in the periphery and brain tissue (Figure 4, C 
and D, and Figure 5, C and D). Additionally, we also examined 
gliosis, trichrome staining, elastin, laminin, and collagen type IV, 
and these features were all identical between mouse and human 
lesions (Figure 4, E and N, Figure 5, E and N, and Table 3).
We also examined mouse lesions at the ultrastructural level using 
transmission electron microscopy. Murine cavernous malformations 
showed endothelial cells lining vascular channels with associated basal 
lamina (Figure 6A). Some of the larger channels showed segmental 
multilayering (lamellated appearance) of the basal lamina (Figure 6B). 
The most dilated channels showed focally marked attenuation of the 
endothelial cells (Figure 6C); however, tight junctions were identified 
between cells, and definitive gaps were not seen. Connective tissue 
composed mainly of collagen fibers separated the vascular channels 
(Figure 6D). Pericytes or astrocytic foot processes were missing, as 
seen in human lesions. Foci of mononuclear inflammatory cells were 
also seen (Figure 6E), including hemosiderin-laden macrophages (Fig-
ure 6F). Ultrastructural analysis of murine CCM lesions was similar to 
that described in human CCMs (45), further solidifying the fidelity of 
the mouse model to the human disease.
Murine cavernous malformations can be detected and followed noninva-
sively by MRI. MRI is used to document the natural history of human 
cavernous malformations and will be necessary for prospective thera-
peutic trials in both mice and humans. We thus employed monthly 
live MRI studies to follow the onset and progression of disease in 
mice until at least 6 months of age (Figure 7). As in humans (24), 
mice lacking Pdcd10 had an earlier onset of disease, with a more 
severe phenotype than Ccm2. All Pdcd10 mice studied at 1 month of 
age had lesions, whereas no Ccm2 mice had yet developed lesions by 2 
months of age (Figure 7K). Mice with Pdcd10 mutations had a greater 
disease burden when assessed by total lesion burden (Figure 7L) or 
by number of complex lesions (increased signal intensity within the 
lesion; Figure 7M). Cavernous malformations were fully penetrant 
in mice with Ccm2 LOH at 6 months of age and most had lesions at 
4 months, at which time the disparity between the genotypes began 
to narrow. This parity reflected not only the increased burden of dis-
ease in Ccm2, but also the onset of death in the most severely affected 
Pdcd10 mice. Mice of both genotypes began to die of hemorrhage, 
but mortality was greater in mice with LOH for Pdcd10 (Figure 7N), 
a finding that reflects the reported experience in humans (24).
??????????
Although CCM has been associated with mutations in 3 distinct 
loci, it has been clinically treated as a single pathophysiologic entity. 
In this manuscript, we describe for what we believe is the first time 
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find that mutations of both PDCD10 and CCM2 result in a com-
mon pathologic expression of disease in both humans and mice. 
Surprisingly, this common disease endpoint does not constitute 
proof of a common disease mechanism. Whereas our previous work 
and the work of others found that Ccm2 and Krit1 play similar roles 
in embryonic development, in vitro cell biology, and cell signaling 
(9, 10, 12, 13), these roles differ from those we observe with Pdcd10. 
Unlike Krit1 and Ccm2, Pdcd10 is not required for development 
of the branchial arch arteries that connect the heart to the aorta. 
Rather, Pdcd10 has an essential, nonendothelial role in develop-
ment not shared with Krit1 or Ccm2 as well as an essential function 
in venous maturation. We further observe differences in cell biol-
ogy and signaling between PDCD10 and KRIT1 or CCM2; whereas 
the loss of KRIT1 or CCM2 leads to RhoA activation, increased Rho 
kinase activity, myosin light chain phosphorylation, and actin stress 
fiber formation (9, 12, 13), we do not observe activation of this sig-
naling pathway in cells depleted of PDCD10. Instead, we found that 
PDCD10 signals primarily through the GCKIII family of kinases.
The similarity in human CCM disease caused by mutations in 
KRIT1, CCM2, and PDCD10 have led to an assumption that the 
proteins encoded by these genes function in a common signal-
ing pathway. This assumption has been supported by experi-
mental evidence showing binding between ectopically expressed, 
epitope-tagged proteins (7, 8). However, the complexities of sig-
naling pathways and pathophysiology allow for multiple mecha-
nisms to converge on a common disease phenotype (Figure 8A). 
An example is hypertrophic cardiomyopathy, which was consid-
ered 1 disease until molecular genetics revealed that 2 different 
mechanisms (sarcomere function or metabolism), each affected 
by distinct genes, both result in pathologic hypertrophy (Figure 
8B and ref. 46). We propose that a similar scenario is involved in 
the pathogenesis of CCM (Figure 8C).
There is controversy concerning the signaling pathways affect-
ed by PDCD10. Several reports suggest an essential role for bind-
ing GCKIII family serine-threonine kinases (16, 21–23). However, 
a recent characterization of mice carrying a different conditional 
allele of Pdcd10 showed that the loss of Pdcd10 in endothelial 
cells substantially blocks VEGFR2 signaling and inhibits the ear-
liest stages of developmental angiogenesis (47). The implication 
of VEGFR2 signaling through MAP kinases agrees with a previ-
ous report linking GCKIII kinases and ERK signaling (20). Our 
data contrast with these reports; we observe that the absence of 
Pdcd10 in vivo leads to a localized vascular defect at a much later 
developmental stage, inconsistent with a panendothelial block 
of VEGF signaling. In cell culture, we have not found any inter-
action between PDCD10 and VEGF or ERK signaling (Supple-
mental Figure 11). We suspect that this disparity may be due to a 
difference in knockout strategy; however, our confidence in our 
allele is bolstered by our ability to induce CCM disease. Our data 
support the model that PDCD10 signals through the GCKIII 
family kinases, as we have observed in human endothelial cells 
and in Drosophila that PDCD10 binds to GCKIII family kinases 
and both are required for lumen formation. Previous reports have 
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with KRIT1/CCM2 signaling (23). By direct comparison of Ccm2 
and Pdcd10 in mouse and cell biology, however, our data suggest 
that PDCD10 signaling is distinct from the CCM2-RhoA axis.
The nature and severity of disease in familial forms of CCM in 
comparison with sporadic CCM suggested a genetic mechanism 
consistent with Knudson’s 2-hit hypothesis (33): LOH for a CCM 
gene induces lesions. Limited evidence to support this theory has 
come from a few human surgical samples amid multiple cases in 
which the second genetic hit could not be found (27, 28). Further 
supportive evidence comes from mice with heterozygous mutations 
for Krit1 or Ccm2 that have been mated into strains with high rates 
of spontaneous mutations. Mice heterozygous for Krit1 develop 
CCM lesions on either a p53- or Msh2-null background, whereas 
mice heterozygous for Ccm2 develop lesions only on the p53-, but 
not the Msh2-null background (35, 36). Whereas these models 
provide suggestive evidence of LOH and employ stochastic events 
to induce CCM formation, LOH was not demonstrated at either 
locus, nor can the LOH hypothesis be supported for all CCM genes, 
as Ccm2+/–;Msh2–/– mice do not develop CCMs. These models also 
do not rule out a role for mutations in other, non-CCM genes and 
do not control tissue specificity of mutation. The penetrance of 
CCMs in these models is incomplete, complicating the use of these 
models in prospective trials to study therapeutics or natural history 
of CCM disease. Concurrent development of neoplasms in both 
the p53- and the Msh2-null backgrounds also adds confounding 
physiological stressors and increases the mortality of the animals. 
In contrast, we employ a strategy that allows direct testing of the 
LOH mechanism in CCM disease. Using an inducible 
Cre-recombinase, we have targeted gene-specific LOH 
for both Pdcd10 and Ccm2 to the endothelium of mice. 
In the case of both genes, we have found that LOH is 
sufficient to cause a fully penetrant CCM phenotype 
that recapitulates every key pathologic and radiologic 
hallmark of human disease.
Much work remains to translate the observations 
and insights regarding disease signaling mechanisms 
into viable therapeutic strategies in patients. This work 
underscores the importance of carefully considering 
disease mechanisms in a genotype-specific manner. The 
availability of faithful, genotype-specific, and highly 
penetrant mouse models of CCM disease unlocks the 
tremendous opportunities to study the natural his-
tory of lesion genesis and progression as well as opportunities for 
preclinical testing of therapeutic interventions. In order for mouse 
models of CCM disease to be useful in informing human studies, 
the same tools used to follow patients with CCM need to be devel-
oped for serial observation of affected mice. We have demonstrated 
that noninvasive MRI of live mice, the same modality used to follow 
CCM in humans, can detect and follow murine CCMs. Although 
our mouse models share a measurable mortality, as with humans, 
they are compatible with prolonged survival and serial, noninvasive 
observation. The ability to follow these mice noninvasively over time 
is a crucial prerequisite for judging the effectiveness of any preclini-
cal therapeutic strategy in the future and for testing the timing and 
intensity of LOH required for lesion formation. Our mouse models 
of CCM phenocopy human disease closely, supplanting previously 
available surrogate phenotypes, and are a powerful new tool in the 
armamentarium to decipher and combat CCM disease.
???????
Mouse strains. The Ccm2 conditional knockout mice have been previ-
ously described (9). A construct for the conditional allele of Pdcd10 was 
derived from genomic sequence obtained from a BAC clone (RP22 library; 
Invitrogen). The construct extended from a SacII site 5! of exon 4 through 
an ApaI site 3! of exon 8. The construct contained inserts as outlined in 
Supplemental Figure 1, including LoxP sequences at a KasI site just 5! of 
exon 4 and at a EcoRI site just 3! of exon 8. All mice were backcrossed into 
the C57BL/6J strain. Experiments performed prior to the fifth cross were 
performed with littermate controls. LacZ reporter mice (R26R1), Tie2-Cre 
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Pathologic findings in human and murine CCMs
Genotype Human CCM2 Murine Ccm2 Human PDCD10 Murine Pdcd10
Trichrome + + ++ ++
Iron + + ++ ++
Elastin – – – –
CD34 + NA + NA
CD31 NA + NA +
Laminin + + + +
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mice, and PDGFb-iCreERT2 mice were generously provided by Phil Soriano 
(Fred Hutchinson Cancer Research Center, Seattle, Washington, USA, and 
Mount Sinai School of Medicine, New York, New York, USA), Masashi 
Yanagisawa (University of Texas Southwestern Medical Center at Dallas, 
Dallas, Texas, USA), and Marcus Fruttiger (University College London 
Institute of Ophthalmology, London, United Kingdom) via Holger Ger-
hardt (London Research Institute — Cancer Research UK, London, United 
Kingdom), respectively. HPRT-Cre, Nestin-Cre, and Tomato-EGFP reporter 
mice were obtained from The Jackson Laboratory. Genotypes were deter-
mined by PCR analysis of genomic DNA isolated from either ear biopsies 
or yolk sac tissues using primers outlined in Supplemental Figure 1. Prim-
er sequences were as follows: primer W: 5!-GCAATCCATCTTGTTCAAT-
GGC-3!, primer X: 5!-CGTAGGTCAGGGTGGTCACG-3!, primer Y: 
5!-TGAAAGAGGACATACTGGAGAGGC-3!, prim-
er Z: 5!-AAGGACAAGAAAGCACTGTTGACC-3!. 
Tamoxifen (Sigma-Aldrich) was resuspended in 
corn oil (Sigma-Aldrich), and 40 ng was given as an 
i.p. injection to mouse pups on perinatal day 1.
MRI of mouse brains. All MRI experiments were con-
ducted on a 7T Bruker Biospec 70/30 USR scanner 
(Bruker Biospin MRI Inc.) equipped with a BGA12S 
gradients set. A combination of volume-transmit–
only radio frequency coil (internal diameter: 72 mm) 
and a quad-surface-receive–only coil (internal diam-
eter: 1.5 cm) were used. For live scans, mice were 
anesthetized in 2.5% isoflurane and then placed into 
the scanner on top of circulating heated water. Dur-
ing the scans, mice were monitored for temperature 
and respiration, with isoflurane concentration and 
water bath temperature adjusted to maintain a body 
temperature between 35.8°C and 37.6°C and respi-
ration between 75 and 100 breaths/min. A gradient 
recalled echo sequence was used to acquire coronal 
slices spanning the whole brain. Sequence param-
eters were as follows: repetition time, 328 ms; echo 
time, 5.4 ms; flip-angle, 40°; 12 averages, in-plane-
resolution, 125 µm " 125 µm; and slice thickness, 0.5 mm.
For postmortem specimens, mouse skulls were fixed in 4% formaldehyde 
for at least 3 days before the brain was imaged with the skull intact. Post-
mortem MRI scanning allows a high-resolution coverage of the brain at 
the expense of longer scan time. High-resolution 3D gradient echo was 
acquired using the same scanner configuration described above, with iso-
tropic voxel size of 78 µm " 78 µm " 78 µm over 9 hours. Other sequence 
parameters were as follows: repetition time, 250 ms; echo time, 7.5 ms; flip 
angle, 30°; and 2 averages.
Histology. Embryo and mouse CCM lesions were studied with antibodies 
to PECAM (1:250 dilution, clone MEC13.3; BD Biosciences) and PDCD10 
(1:50 dilution, Prestige Antibody; Sigma-Aldrich). Improved visualization 
on paraffin sections was obtained using a biotinylated tyramide signal 
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amplification (TSA) kit (PerkinElmer) according to the manufacturer’s 
instructions. To demonstrate tissue specificity of PDFGb-iCreERT2, brains 
from mice carrying a LacZ reporter allele were fixed and then stained 
with X-gal as previously described (48). Brains from mice carrying the 
Tomato-EGFP reporter allele were fixed and then embedded into OCT (Fish-
er Scientific) for fluorescent frozen sections. H&E staining of embryos was 
performed using standard procedures.
For histology of adult mouse brains, mouse skulls were fixed in 4% form-
aldehyde for at least 3 days or zinc-buffered formalin overnight before the 
brain was removed and sliced into 4 coronal sections. These sections were 
embedded into paraffin by standard techniques. Prussian blue staining 
for iron and Masson’s trichrome staining of mouse brain sections were 
performed using the Artisan system (DAKO) according to manufacturer’s 
instructions. Staining for elastin, laminin, and collagen IV was performed 
by the Immunohistochemistry Research and Development Lab at ARUP 
Laboratories. Human CCM samples were stained in the same way as adult 
mouse brains except for CD34 staining, which was performed by the Cen-
tral Labs at Intermountain Medical Center (Murray, Utah, USA).
Fluorescent staining of mouse retinas. Mice were anesthetized using Avertin 
(2,2,2-tribromoethanol, 0.4 mg/g; Acros Organics) and perfused with fluo-
rescently conjugated tomato lectin (Vector Labs) as previously described 
(49) at a dose of 5 µg/g body weight. After 5 minutes, mice were perfused 
with saline and then with 4% formaldehyde. Retinas were then extracted, 
stained, and mounted as previously described (50).
Analysis of mouse embryos. Confocal immunofluorescence of embryos and 
fetal ultrasound were performed as previously described (9).
Transmission electron microscopy. Samples were fixed in 1% formaldehyde, 
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer with 8 mM CaCl2 
and 2.4% sucrose, pH 7.4, for at least 3 days. Samples were then rinsed in 
0.1 M cacodylate buffer, postfixed in 2% osmium tetroxide in 0.1 M caco-
dylate buffer, rinsed in type I water, and then enbloc stained with satu-
rated aqueous uranyl acetate. Samples were dehydrated through a graded 
series of ethanols, followed with final dehydration in acetone, and then 
infiltrated and embedded in an epoxy resin.
Thick sections and thin sections were cut on a Leica EM UC6 ultramicro-
tome (Leica Microsystems). The thick sections were cut with glass and the thin 
sections were cut with a diatome diamond knife. Thick sections were dried on 
glass slides and were stained with 1% toluidine blue O in 1% aqueous sodium 
borate. Thin sections were placed on 135 mesh copper hex grids and stained 
sequentially with saturated aqueous uranyl acetate and Reynolds lead citrate.
Sections were examined on an FEI Tecnai T-12 transmission electron 
microscope (FEI) at 80 KV. Images were taken on Kodak 4489 electron 
microscope film, developed with Kodak D-19 developer, fixed, washed, 
and dried. The negatives were scanned on an Epson Perfection Photo 4990 
flatbed scanner.
Cell culture. HUVEC and HMVEC were obtained from Lonza and grown 
according to the manufacturer’s instructions in EGM-2 media (HUVEC) or 
EGM-2MV media (HMVEC). Human embryonic kidney (HEK 293T) cells 
(ATCC) were grown in DMEM (Gibco; Invitrogen) with 10% fetal bovine 
serum (Bio-West) supplemented with antibiotics. EAHY cells were generously 
provided by Andrew Weyrich (University of Utah) and were grown in DMEM 
with 10% fetal bovine serum and HAT supplement (Sigma-Aldrich).
Transfection of ECs with siRNAs. Human CCM2 and PDCD10 siRNAs were 
obtained from Dharmacon. Luciferase GL2 duplex or nontargeting siRNA 
(Dharmacon) were used as controls. EC transfection with siRNAs was car-
ried out in growth media with 1% serum. Details of the siRNA transfection 
protocol have been described previously (51).
RT-PCR. Total RNA was extracted from EC vasculogenesis assay at indi-
cated time points or from siRNA-treated ECs using the ToTALLY RNA 
Isolation Kit (Ambion) according to the manufacturer’s instructions. RNA 
(1 µg) was reverse transcribed using AccuScript High Fidelity 1st strand 
cDNA synthesis kit (Stratagene; Agilent). RT-PCR amplification used 
the following primers: forward: 5!-AGACTTCACGGAGTCCCTTC-3!, 
reverse: 5!-AGAAGGTCTGAAGTATTAAGTTGG-3!. For quantitative 
real-time PCR, total RNA was extracted from cultured endothelial cells 
or from embryos using the NucleoSpin RNA II Kit (Clontech) according 
to the manufacturer’s instructions. Reverse transcription was performed 
with random primers using the RETROScript Kit (Ambion). Quantitative 
PCR was performed with TaqMan assays (Applied Biosystems) for human 
CCM2, PDCD10, GAPDH, STK24, STK25, and MST4 or mouse Pdcd10 and 
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CCM2 and PDCD10 transcripts were normalized to GAPDH for compari-
sons. RT-PCR primers for embryonic Pdcd10 transcripts were as follows: 
primer 4F: 5!-TTCACCGAGTCCCTCCTTCG-3!; primer 7/8R: 5!-GAACA-
CATTTATTGCCTTGCCATC-3!; primer 1F: 5!-AAGTCCGTGCCTCAGTT-
GCC-3!; and primer EGFP-R: 5!-TCCTCGCCCTTGCTCACC-3!.
Immunofluorescent cell staining. Glass chamber slides (Nalge Nunc; Thermo 
Fisher) were coated with human fibronectin (Biomedical Technologies 
Inc.), and transfected cells were seeded at 50,000 cells per well. Cells were 
fixed in 4% formaldehyde and actin cytoskeleton was visualized using flu-
orescently conjugated phalloidin (Molecular Probes; Invitrogen). Images 
were obtained with an Olympus FV300 confocal microscope.
Endothelial cell vasculogenesis in 3D collagen matrices. This assay was per-
formed as previously described (9, 38).
Immunoprecipitation and Western blotting. An expressed sequence tag (EST) 
for human PDCD10 (IMAGE: 3050540) was obtained from ATCC and cloned 
into a pcDNA3.1 Hygro+ plasmid (Invitrogen) modified to encode an N-ter-
minal FLAG tag. ESTs for Drosophila Pdcd10 and GCKIII were obtained from 
the Drosophila Genomics Resource Center and cloned into a pcDNA3.1 
Hygro+ plasmid modified to encode an N-terminal FLAG tag (Pdcd10) or 
HA tag (GCKIII). PDCD10∆18 constructs were made using nested PCR with 
primers designed to overlap and omit the 54 nucleotides encoding those 18 
amino acids. Plasmids were transfected into EAHY or HEK 293T cells using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruc-
tions, with a reduced dosage of DNA and lipofectamine for EAHY cells. Two 
days after transfection, cells were scraped into lysis buffer (50 mM Tris-HCl at 
pH 7.5, 100 mM NaCl, 0.5% Triton X-100) supplemented with protease and 
phosphatase inhibitors and 1 mM DTT. A portion of cell lysate was retained 
as whole cell lysate and the rest precleared with normal mouse IgG conjugat-
ed to agarose beads (Santa Cruz Biotechnology Inc.) at 4°C for 1 hour, then 
incubated with anti-FLAG resin at 4°C for 2 hours. The beads were washed 3 
times with lysis buffer, and bound proteins were eluted using Laemmli sam-
ple buffer. Presence of FLAG-tagged PDCD10 proteins was detected using the 
anti-FLAG M2 antibody (Sigma-Aldrich). Presence of HA-tagged GCKIII was 
detected using an anti-HA antibody (Santa Cruz Biotechnology Inc.). Near-
infrared secondary antibodies (LI-COR Biosciences) were used to probe the 
blots, which were visualized using the Odyssey system (LI-COR Biosciences).
Rabbit polyclonal antibody against PDCD10 was from Proteintech Group. 
Rabbit antibodies against phospho-myosin light chain (Thr18/Ser19), phos-
pho-VEGFR2 (Tyr1175), total VEGFR2, phospho-PLC" (Tyr783), total PLC", 
phospho-ERK1/2 (Thr202/Tyr204), and total ERK1/2 were from Cell Sig-
naling Technology. #-Actinin antibody (clone H-2) was from Santa Cruz Bio-
technology Inc. HRP-conjugated secondary antibodies were from Jackson 
ImmunoResearch. Western blots were developed using the ECL Plus Western 
blotting reagent (GE Healthcare) and Kodak Biomax MR film.
Drosophila strains. The GAL4/UAS system was used for tissue-specific 
RNAi knockdown (43). The driver used was btl-GAL4 (42), and RNAi tar-
geting constructs v109453 (against Pdcd10) (41), v106841 (against Pdcd10) 
(41), and v49559 (against GCKIII) (44) were obtained from the Vienna Dro-
sophila RNAi Center. For rescue experiments, full-length cDNAs for Dro-
sophila Pdcd10 were cloned into a pUAST transformation vector containing 
an attb site for site-specific transformation (52) provided by Carl Thummel 
(University of Utah). Transgenes were injected into docking sites VK00027 
(53) and attp0016 (52) by Genetic Services Inc., and homozygous lines were 
established by standard methods.
For cDNA rescue experiments, flies homozygous for the cDNA rescu-
ing construct on the third chromosome were crossed to a homozygous 
btl-GAL4, UAS-GFP driver line on the second chromosome to generate 
transheterozygote flies (btl-GAL4, UAS-GFP/+; UAS-Rescue/+). Males of this 
genotype were then crossed to virgin females homozygous for the RNAi 
targeting construct located on the second chromosome. GFP expression 
indicated the presence of the btl-GAL4, UAS-GFP transgenes. All of these 
larvae contain 1 copy of the RNAi targeting construct, and half also have 
the cDNA rescue transgene. Results shown used the v109453 line, which 
targets the 3! UTR of Pdcd10. The v106841 line showed similar results.
Analysis of tracheal tube formation in Drosophila larvae. Animals were scored 
at the prewandering third instar larval stage for tracheal defects. Animals 
were graded by scoring air filling in primary sprouts emanating from the 
dorsal trunk. All primary sprouts were scored bilaterally (at least 12 per 
larva). The animals were categorized as having severe, moderate, or mild 
defects or wild-type if they had 3 or more of the following defects: (a) severe 
defects were truncations before the first bifurcation of the primary side 
branches or immediately after branching; (b) moderate defects represent-
ed gaps in air filling with filled tubes on both sides; (c) mild defects were 
loss of air filling only in the fine terminal tubes. In the event that more 
than 1 criterion was met, the more severe category was selected. If animals 
had fewer than 3 branches with a given defect, the less severe category was 
selected. Only animals with no defects were categorized as wild type.
Mouse and human experiments. All mouse experiments were approved by the 
University of Utah Institutional Animal Care and Use Committee. Human 
tissue samples were obtained with written informed consent and provided 
by Connie Lee and Amy Akers (Angioma Alliance, Norfolk, Virginia, USA) 
and Randy Jensen (University of Utah). Human experiments were approved 
by the Institutional Review Board of the University of Utah.
Statistics. For actin stress fiber content, and for in vitro lumen formation 
with GCKIII kinases, we performed ANOVA with Tukey’s post hoc analy-
sis with an # value of 0.05. For in vitro lumen formation time course for 
PDCD10, we performed statistical comparisons between treatment groups 
with a 2-tailed paired-sample t test with an # value of 0.05. For the tracheal 
tube formation rescue experiment, we performed a $2 test for independence 
with an # value of 0.05 (degrees of freedom = 9). For CCM penetrance and 
lesion content, we performed a 2-tailed t test with an # value of 0.05.
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Supplemental Figure 1.  Knockout design for Pdcd10.  Ubiquitous deletion of Pdcd10
results in early embryonic death.  (A) Alleles of Pdcd10 are shown. The floxed allele resulting
from the targeting strategy includes loxP sites flanking exons 4-8 and places the enhanced green
fluorescent protein (EGFP) in position to splice onto exon 3 in a fusion transcript resulting from
the recombined allele.  Genotyping primers are indicated by the letters W, X, Y and Z.  (B)
Genotyping by PCR using combinations of primers W, X, Y, and Z distinguishes the possible
genotypes.  (C) The wildtype and fusion transcripts are illustrated with exons outlined. The
location of primers for RT-PCR are shown.  (D) Results of RT-PCR performed on cDNA from




 mice.  (E)
Gross photos of E8.0 mouse embryos on dissection.  Wildtype is shown in (E, left panel),
Pdcd10 knockout in (E, right panel).  Even at this early stage, the knockout embryo has growth
arrested and is smaller than its wildtype littermate.  Scale bars = 200 µm.
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Supplemental Figure 2.  Endothelial knockout of Pdcd10 does not affect establishment of
circulation or cardiac structure.  Neural knockout of Pdcd10 is viable.  (A-B) Whole-mount
fluorescent staining for CD31 in E9.5 Pdcd10
flox/–
 (A) and Pdcd10
flox/–
; Tie2-Cre (B) embryos.
Arrows denote the dorsal aorta. (C-D) Hematoxylin and CD31 staining in E12.5 Pdcd10
flox/+
;
Tie2-Cre (C) and Pdcd10
flox/–
; Tie2-Cre (D) embryos.  (E-F) Hematoxylin and !-smooth muscle
actin staining in E12.5 Pdcd10
flox/+
; Tie2-Cre (E) and Pdcd10
flox/–
; Tie2-Cre (F) embryos.  a,
atrium; v, ventricle; BAA, branchial arch artery; m, myocardium; PV, pulmonary valve. (G-H)
Hematoxylin and eosin staining in E12.5 Pdcd10
flox/+
; Nestin-Cre (G) and Pdcd10
flox/–
; Nestin-
Cre (H) embryos.  Asterisks denote the cardinal veins.  Arrows denote the dorsal aorta.  Scale
bars = 500 µm.
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Supplemental Figure 3.  siRNA effectively reduces levels of PDCD10, STK25, STK24, and
MST4.  (A) Quantitative PCR to detect PDCD10, STK25, STK24, and MST4 was performed on
cDNA made from the RNA of human endothelial cells to assess knockdown.  (B) Western blot
for PDCD10 to confirm knockdown.
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Supplemental Figure 4. Pdcd10 signals through GCKIII kinases in lumen formation. (A)
Quantification of lumen area over time for human umbilical vein endothelial cells after treatment
with PDCD10 siRNA or control siRNA directed against Luciferase. (B) Toluidine blue staining
of lumen formation assay. Lumens are shown with arrowheads. (C) Quantification of lumen area
at 24 hours for cells treated with siRNA directed against each of the GCKIII kinases or
Luciferase control (5 fields per time point in 3 independent experiments). (D)
Immunoprecipitation for HA-tagged Drosophila GCKIII using full length Drosophila Pdcd10
(DmPdcd10) or Drosophila Pdcd10 with 18 amino acid deletion (DmPdcd10!18).  Results are
representative of 3 independent experiments.  (E) Quantification of tracheal tube lumen
formation defects in Drosophila with RNAi knockdown of Pdcd10 with or without rescue
constructs (N " 64 for each genotype). Note: for rescue experiments only ~50% of all larvae
contained the corresponding rescue transgene since they were generated by mating rescue
heterozygous males (btl-GAL4, UAS-GFP/+; UAS-Rescue/+) to homozygous UAS-RNAi virgin
females. (F) Quantification of 3D endothelial cell lumen area with combinatorial knockdown of
human GCKIII kinases (5 fields per time point in 3 independent experiments).  Data indicate
mean ± SD.  Scale bars = 50 #m.
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Supplemental Figure 5.  Loss of Pdcd10 or GCKIII results in failure of tracheal tube
lumenization in Drosophila.  (A) The tracheal network of a Drosophila larva.  A UAS-GFP
transgene was used to label tracheal cells (left panel).  Brightfield images of the same larva show
air filling in lumens (middle panel).  A cartoon representing the lumenized tube network (cyan)
appears in the rightmost panel.  (B-D) Tracheal tube lumen formation in flies expressing control
RNAi (B), RNAi directed against Pdcd10 (C), or RNAi directed against GCKIII (D) under the
control of the tracheal-specific btl-GAL4 driver.  Arrowhead (in cartoon panel of B) indicates the
primary trunk of a tracheal tube (where lumen truncation would indicate a severe phenotype),
and arrows indicate the fine terminal branches (where lumen truncation would indicate a mild
phenotype). Loss of Pdcd10 or GCKIII results in similar air-filling defects. GFP expressing
tracheal cells that lack air-filled lumens are outlined in red on the cartoon panels of C-D.  Scale
bars in (A) = 500 µm.  Scale bars in (B-D) = 200 µm.
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Supplemental Figure 6.  PDGFb-iCreER
T2
 activity is specific to the endothelium.  (A) X-gal
staining (blue) of brain from a 6 month old PDGFb-iCreER
T2
; Rosa26-LacZ mouse that was
given tamoxifen at birth.  (B) Close-up of the boxed area in panel (A).  (C-D) X-gal (blue) and
CD31 (brown) staining of brain from a 6 month old PDGFb-iCreER
T2
; Rosa26-LacZ mouse that
was given tamoxifen at birth.  (E-G) CD31 (magenta) staining of brain from a 12 day old
PDGFb-iCreER
T2
; Rosa26-ACTB-tdTomato,-EGFP mouse that was given tamoxifen at birth.
Cre activation converts ubiquitous tomato expression (not shown) to EGFP expression (green).
(H-J) Neuron-specific enolase (NSE, magenta) staining of brain from a 12 day old PDGFb-
iCreER
T2
; Rosa26-ACTB-tdTomato,-EGFP mouse that was given tamoxifen at birth.  Cre
activation converts ubiquitous tomato expression (not shown) to EGFP expression (green).  Scale
bars in (A-B) = 1 mm.  Scale bars in (C-J) = 100 µm.
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Supplemental Figure 7.  LOH of either Ccm2 or Pdcd10 results in a range of vascular
malformations.  Both mouse models of CCM exhibit the same spectrum of pathology. Both the
Pdcd10 (A, C, E, and G) and Ccm2 (B, D, F, and H) induced endothelial knockout models
develop vascular lesions that exhibit the previously described spectrum of CCM pathology.
Examples shown here include lesions consistent with solitary telangiectasias (A-B), multichannel
"pristine" caverns (C-D), complex multichannel lesions with organizing thromboses (arrows in
E-F), and multiple small caverns associated with heavy hemosiderin staining (arrowheads in G-
H).  Scale bars = 200 !m.
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Supplemental Figure 8.  Loss of Pdcd10 protein from Pdcd10 (but not Ccm2) vascular
lesions.  An antibody against Pdcd10 does not stain endothelial cells of a CCM lesion from a
Pdcd10 induced knockout mouse (upper panel) but does stain the endothelial cells of a CCM
from a Ccm2 induced knockout mouse (bottom panel).  Arrows indicate endothelial cells.  Scale
bars = 50 µm.
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Supplemental Figure 9.  Murine CCMs occur in the retinal vasculature.  Lectin stained


















 mouse (E-F).  All mice were given
tamoxifen at birth.  (C) Close-up of the boxed, CCM-containing area in (B).  (F) Close-up of the
boxed, CCM-containing area in (E).  Scale bars for all panels = 1 mm, except for panel (F),
which is 500 µm.
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Supplemental Figure 10.  Neural-specific deletion of Ccm2 does not result in CCMs.  (A-F)
Histology of Ccm2
flox/–
; Nestin-Cre mouse brain at 6 months (A-B), 7 months (C-D), and 8
months (E-F).  Staining is Prussian blue for hemosiderin with nuclear fast red counterstain.  No
lesions are found in these brains, and no hemosiderin is apparent.  Scale bars = 1 mm.  (G) Table







Supplemental Figure 11.  Loss of PDCD10 does not affect VEGFR2-MAPK signaling.
Western blot for VEGFR2, PLC!, and ERK1/2 phosphorylation after stimulation of HMVECs
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The Drosophila larval tracheal system is composed of approximately 10,000 
interconnected tubes that serve to transport oxygen and other gases throughout the body.  
In order to achieve this complete interconnectivity, the tracheal system must first undergo 
extensive branching and fusion steps that begin during embryogenesis and continue 
throughout larval development (Samakovlis et al., 1996).  The genes involved in 
mediating these processes may also control similar processes seen in other organisms.  
A forward genetic screen of the X chromosome was previously conducted to isolate 
lethal mutations affecting branching and lumen formation in tracheal terminal cells 
(Metzstein and Krasnow, unpublished results).  Tracheal terminal cells are specialized 
cells that undergo subcellular branching and tubulogenesis, and are responsible for 
transporting gases and exchanging gases in hypoxic tissues (Jarecki et al., 1999).  Thirty-
two lines with mutations affecting different aspects of branching and lumen formation 
were identified.  Of these thirty-two, we focused on five lines in which terminal cells 
undergo essentially normal branching, but are unable to generate a functional lumen. 
Our mapping and sequencing data allowed us to identify specific candidate genes.  
Some of these genes may use known cellular processes that are thought to regulate lumen 
formation, while other candidates represent unknown functions.   
 
  106 
Mapping experiments have also allowed for the identification and molecular 
cloning of one causative gene as Zpr1 (Zinc-finger protein 1), an evolutionarily 
conserved protein characterized by two C4 zinc fingers and two conserved homology 
domains.  We show here that Zpr1 is required for lumenogenesis in terminal cells, and is 
also involved in regulating branch outgrowth.   
Zpr1 was initially identified as a protein that was able to bind the intracellular tail 
of the inactive EGFR (Galcheva-Gargova et al. 1996).  The EGFR has previously been 
shown to be involved early in tracheal cell migration, and is necessary for maintaining 
the structural of the tracheal system, but specific downstream effectors have not been 
identified in the tracheal system (Cela and Llimargas, 2006; Nishimura et al., 2007).  We 
show by epistasis experiments as well as in our air-filling assay, that mutations in the 
EGFR phenocopy Zpr1 lumenless mutants.  To our knowledge, this is the first in vivo 
evidence that demonstrates that Zpr1 functions downstream of the EGFR, and that Zpr1 
activity is required for a specific developmental process.  We have yet to show whether 
there is a direct physical interaction between Zpr1 and the FGFR, but we show that that 
Zpr1 lies downstream of the FGFR, a previously uncharacterized interaction. 
Consistent with out data that Zpr1 lies downstream of multiple RTKs, we show 
that the null mutations in the two receptor tyrosine phosphatases (RPTPs) expressed in 
tracheal system result in excessive cytoplasmic outgrowth and lumenless cells (Jeon and 
Zinn, 2009).  This result on its own may be interpreted as an indication that these RPTPs 
are not very specific and may be affecting other RTKs.  Combining our genetic evidence 
showing that multiple RTKs ar feeding into the Zpr1 pathway with the previous data 
supporting a negative regulation by RPTPs, a more complex signaling cascade arises.   
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The finding that Zpr1 lies downstream of multiple RTKs allows us to propose a 
model that provides the cell with a method for interpreting various positional cues that 
help the cell determine whether it has reached hypoxic target tissue.  In our model, 
hypoxic tissue secreting FGF serves as a long-range signaling molecule that instructs the 
outgrowth and active migration of terminal cells towards hypoxic tissue.  Hypoxic tissue 
then secretes EGF as a short-range signaling molecule that induces lumen formation.  
Since lumen formation is an important step in mediating gas exchange between hypoxic 
tissue, the possible cross talk or redundancy between the FGFR and EGFR signaling 
cascades provide the cell with both, a fail safe that can ensure lumen formation occurs as 
well as an alternative method for modifying the amount of lumenogenesis that occurs 
during hypoxic conditions.  
Evidence also shows that upon EGFR activation, Zpr1 can interact with the 
eukaryotic translation elongation factor 1A (eEF1A) or bind multiprotein complexes 
formed by the survival motor neurons 1 (SMN1) protein and that both of these 
interactions result in the redistribution and nuclear accumulation of Zpr1 (Gangwani, et 
al., 1998; Galcheva-Gagova et al., 1998).  We show that RNAi knockdown of the two 
other known Zpr1 binding partners eEf1α and SMN1 also result in lumenless terminal 
cells.  These results support previously published reports suggesting that FGFR is a 
genetic modifier of smn mutants, and its over-expression may be sufficient to bypass 
mutations in smn.  
We have now generated some of the tools that will allow us to investigate the 
downstream effects of Zpr1 and begin to address its specific role in the nucleus.  The 
generation of tagged versions of Zpr1 will allow us to investigate changes in its 
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subcellular localization in response to different genetic insults.  Specifically it will be 
interesting to test whether over-expression of Zpr1is able to rescue mutations in smn in 
vivo and whether this is can be controlled by FGF signaling.  Altogether we have 
constructed the genetic tools necessary to answer long-standing questions in the SMA 
field.  It remains to be seen if our lumenless terminal cell phenotype adequately 
recapitulates the known phenotypes of Zpr1 loss-of-function mutations in mammalian 
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